# **US Patent & Trademark Office Patent Public Search | Text View**

United States Patent12390662Kind CodeB2Date of PatentAugust 19, 2025Inventor(s)Koponen; Timo et al.

# System and method for proton therapy treatment planning with proton energy and spot optimization

## **Abstract**

Embodiments of the present invention disclose methods and systems for proton therapy planning that includes proton energy and spot optimization that discretizes layers and spots using an optimization algorithm to produce an optimal distribution of layer energies and spots with a relatively smooth dose distribution. The treatment planning algorithms disclosed herein can freely choose the number of spots and the energy levels of the spots. In this way, each spot can be treated as its own layer and is not constrained by the requirements of other spots/layers. Thereafter, the spots defined by the algorithm can be sorted in a list according to energy levels/depth, and the spots can be grouped into blocks according to intensity and location. The blocks can be assigned energy levels based on the corresponding spots, such as an average of all the spots associated with the block. The blocks then are used as the energy layers applied by the proton therapy treatment system.

Inventors: Koponen; Timo (Espoo, FI), Niemela; Perttu (Espoo, FI)

Applicant: Varian Medical Systems International AG. (Cham, CH)

Family ID: 1000008767289

Assignee: SIEMENS HEALTHINEERS INTERNATIONAL AG (Steinhausen, CH)

Appl. No.: 16/838940

Filed: April 02, 2020

#### **Prior Publication Data**

**Document Identifier**US 20210308485 A1

Publication Date
Oct. 07, 2021

## **Publication Classification**

Int. Cl.: A61N5/10 (20060101); G16H20/40 (20180101)

U.S. Cl.:

CPC **A61N5/1031** (20130101); **A61N5/1081** (20130101); **G16H20/40** (20180101); A61N2005/1087 (20130101)

# Field of Classification Search

**CPC:** A61N (2005/1087); A61N (5/103); A61N (5/1031); A61N (5/1043); A61N (5/1081)

#### References Cited

## U.S. PATENT DOCUMENTS

Patent No.	<b>Issued Date</b>	Patentee Name	U.S. Cl.	CPC
4163901	12/1978	Azam	N/A	N/A
4914681	12/1989	Klingenbeck et al.	N/A	N/A
5153900	12/1991	Nomikos et al.	N/A	N/A
5267294	12/1992	Kuroda	N/A	N/A
5550378	12/1995	Skillicorn et al.	N/A	N/A
5610967	12/1996	Moorman et al.	N/A	N/A
5625663	12/1996	Swerdloff et al.	N/A	N/A
5682412	12/1996	Skillicom et al.	N/A	N/A
5757885	12/1997	Yao et al.	N/A	N/A
6198802	12/2000	Elliott et al.	N/A	N/A
6222544	12/2000	Tarr et al.	N/A	N/A
6234671	12/2000	Solomon et al.	N/A	N/A
6260005	12/2000	Yang et al.	N/A	N/A
6379380	12/2001	Satz	N/A	N/A
6411675	12/2001	Llacer	N/A	N/A
6445766	12/2001	Whitham	N/A	N/A

6504899	12/2002	Pugachev et al.	N/A	N/A
6580940	12/2002	Gutman	N/A	N/A
6993112	12/2005	Hesse	N/A	N/A
7268358	12/2006	Ma et al.	N/A	N/A
7453983	12/2007	Schildkraut et al.	N/A	N/A
7515681	12/2008	Ebstein	N/A	N/A
7522706	12/2008	Lu et al.	N/A	N/A
7560715 7500210	12/2008	Pedroni Mayron In et al	N/A N/A	N/A N/A
7590219 7616735	12/2008 12/2008	Maurer, Jr. et al. Maciunas et al.	N/A	N/A N/A
7623623	12/2008	Raanes et al.	N/A	N/A
7778691	12/2009	Zhang et al.	N/A	N/A
7807982	12/2009	Nishiuchi et al.	N/A	N/A
7831289	12/2009	Riker et al.	N/A	N/A
7835492	12/2009	Sahadevan	N/A	N/A
7907699	12/2010	Long et al.	N/A	N/A
8284898	12/2011	Ho et al.	N/A	N/A
8306184	12/2011	Chang et al.	N/A	N/A
8401148	12/2012	Lu et al.	N/A	N/A
8406844 8559596	12/2012 12/2012	Ruchala et al. Thomson et al.	N/A N/A	N/A N/A
8600003	12/2012	Zhou et al.	N/A	N/A N/A
8613694	12/2012	Walsh	N/A	N/A
8636636	12/2013	Shukla et al.	N/A	N/A
8644571	12/2013	Schulte et al.	N/A	N/A
8716663	12/2013	Brusasco et al.	N/A	N/A
8836332	12/2013	Shvartsman et al.	N/A	N/A
8847179	12/2013	Fujitaka et al.	N/A	N/A
8903471	12/2013	Heid	N/A	N/A
8917813	12/2013	Maurer, Jr.	N/A	N/A
8948341	12/2014	Beckman	N/A	N/A
8958864	12/2014	Amies et al. Carlone et al.	N/A N/A	N/A N/A
8983573 8986186	12/2014 12/2014	Zhang et al.	N/A	N/A N/A
8992404	12/2014	Graf et al.	N/A	N/A
8995608	12/2014	Zhou et al.	N/A	N/A
9018603	12/2014	Loo et al.	N/A	N/A
9033859	12/2014	Fieres et al.	N/A	N/A
9079027	12/2014	Agano et al.	N/A	N/A
9149656	12/2014	Tanabe	N/A	N/A
9155908	12/2014	Meltsner et al.	N/A	N/A
9233260	12/2015	Slatkin et al.	N/A	N/A
9258876 9283406	12/2015 12/2015	Cheung et al. Prieels	N/A N/A	N/A N/A
9308391	12/2015	Liu et al.	N/A	N/A
9330879	12/2015	Lewellen et al.	N/A	N/A
9333374	12/2015	Iwata	N/A	N/A
9468777	12/2015	Fallone et al.	N/A	N/A
9517358	12/2015	Velthuis et al.	N/A	N/A
9526918	12/2015	Kruip	N/A	N/A
9545444	12/2016	Strober et al.	N/A	N/A
9583302	12/2016	Figueroa Saavedra et al.	N/A	N/A
9636381 9636525	12/2016 12/2016	Basile Sahadevan	N/A N/A	N/A N/A
9649298	12/2016	Djonov et al.	N/A	N/A N/A
9656098	12/2016	Goer	N/A	N/A
9694204	12/2016	Hardemark	N/A	N/A
9776017	12/2016	Flynn et al.	N/A	N/A
9786054	12/2016	Taguchi et al.	N/A	N/A
9786093	12/2016	Svensson	N/A	N/A
9786465	12/2016	Li et al.	N/A	N/A
9795806	12/2016	Matsuzaki et al.	N/A	N/A
9801594	12/2016	Boyd et al.	N/A	N/A
9844358 9854662	12/2016 12/2016	Wiggers et al. Mishin	N/A N/A	N/A N/A
9884206	12/2010	Schulte et al.	N/A	N/A
9931522	12/2017	Bharadwaj et al.	N/A	N/A
9962562	12/2017	Fahrig et al.	N/A	N/A
9974977	12/2017	Lachaine et al.	N/A	N/A
9987502	12/2017	Gattiker et al.	N/A	N/A
10007961	12/2017	Grudzinski et al.	N/A	N/A
10022564	12/2017	Thieme et al.	N/A	N/A
10071264	12/2017	Liger	N/A	N/A
10080912	12/2017 12/2017	Kwak et al.	N/A N/Δ	N/A N/A
10092774	12/2017	Vanderstraten et al.	N/A	N/A

10188875   122018	10183179	12/2018	Smith et al.	N/A	N/A
10206871   12/2018					
10223193   122018   Iseki   N/A   N/A   N/A   10272044   122018   Zwart et al.   N/A   N/A   N/A   10272044   122018   West et al.   N/A   N/A   N/A   10279184   122018   West et al.   N/A   N/A   N/A   10293184   122018   Pishdad et al.   N/A   N/A   10307615   122018   Ollila et al.   N/A   N/A   N/A   10307615   122018   Ollila et al.   N/A   N/A   N/A   10307615   122018   Ollila et al.   N/A   N/A   N/A   10315047   122018   Sahadevan   N/A   N/A   N/A   N/A   10413755   122018   Sahadevan   N/A   N/A   N/A   N/A   N/A   10449389   122018   Ollila et al.   N/A   N/A   N/A   N/A   10525285   122019   Friedman   N/A   N/A   N/A   10525285   122019   Friedman   N/A   N/A   N/A   10549117   122019   Grittani et al.   N/A   N/A   N/A   10549117   122019   Grittani et al.   N/A   N/A   N/A   N/A   10603514   122019   Boyd et al.   N/A   N/	10206871	12/2018	Lin et al.	N/A	N/A
10258810   122018   Zwart et al.   N/A   N/A   10272916   122018   Ollila et al.   N/A   N/A   N/A   10279196   122018   West et al.   N/A   N/A   N/A   10307614   122018   Schnarr   N/A   N/A   N/A   10307615   122018   Ollila et al.   N/A   N/A   N/A   10315047   122018   Ollila et al.   N/A   N/A   N/A   N/A   10315047   122018   Ollila et al.   N/A   N			_		
10272264   122018   West et al. N/A N/A   N/A   10293184   122018   Pishdad et al. N/A N/A   N/A   10307614   122018   Pishdad et al. N/A N/A   N/A   10307614   122018   Pishdad et al. N/A N/A   N/A   N/A   10307615   122018   Ollila et al. N/A N/A   N/A   N/A   10315047   122018   Sahadevan N/A N/A   N/A   N/A   10413755   122018   Sahadevan N/A N/A   N/A   N/A   10449389   122018   Glimelius et al. N/A N/A   N/A   N/A   10449389   122018   Kuusela et al. N/A N/A   N/A   N/A   10525285   122019   Friedman N/A N/A   N/A   10525285   122019   Friedman N/A N/A   N/A   105353609   122019   Grittani et al. N/A N/A   N/A   10603514   122019   Grittani et al. N/A N/A   N/A   10635609   122019   Bertsche et al. N/A N/A   N/A   10635609   122019   Bertsche et al. N/A N/A   N/A   10660588   122019   Boyd et al. N/A N/A   N/A   10660588   122019   Boyd et al. N/A N/A   N/A   10660588   122019   Boyd et al. N/A N/A   N/A   10680586   122019   Boyd et al. N/A N/A   N/A   106805746   122019   Hesse   N/A N/A   N/A   10755746   122019   Kwak et al. N/A N/A   N/A   10755746   122019   Bartsoksi et al. N/A N/A   N/A   10750746   122003   Matsuda   250492.1   G21K 1/08   200400227104   122008   Failine et al. N/A N/A   N/A   20090003314   122008   Failine et al. N/A N/A   N/A   20090003314   122008   Failine et al. N/A N/A   N/A   20090003314   122009   Failine et al. N/A N/A   N/A   20100119337   122009   Failine et al. N/A N/A   N/A   201001077870   122009   Failine et al. N/A N/A   N/A   201001077870   122009   Failine et al. N/A N/A   N/A   201001077876   122009   Failine et al. N/A N/A   N/A   201001077876   122009   Failine et al. N/A N/A   N/A   N/A   101001077876   122009   Failine et al. N/A N/A   N/A   101001077876   122010   Nord et al. N/A N/A   N/A   101001077876   122010   Nord et al. N/A N/A   N/A   101001077876   122010   Nord et al. N/A N/A   N/A   101001077876   122011   Melse et al. N/A N/A   N/A   101001077876   122011   Melse et al. N/A N/A   N/A   N/A   101001077876   122011   Hesse et al. N/A N/A   N/A					
10279196					
10293184   122018					
10307614   122018   Olille et al. N/A N/A   10315047   122018   Olille et al. N/A N/A   10315047   122018   Olille et al. N/A N/A   10413755   122018   Olille et al. N/A N/A   10413755   122018   Olille et al. N/A N/A   10449389   122018   Kuusela et al. N/A N/A   10449389   122018   Kuusela et al. N/A N/A   10549117   122019   Friedman N/A N/A   10549117   122019   Gritani et al. N/A N/A   10603514   122019   Gritani et al. N/A N/A   10603606   122019   Brocken et al. N/A N/A   10606060   122019   Brocken et al. N/A N/A   10666608   122019   Boyd et al. N/A N/A   10666100   122019   Boyd et al. N/A N/A   10662528   122019   Boyd et al. N/A N/A   10662528   122019   Boyd et al. N/A N/A   10702716   122019   Heese N/A N/A   10702716   122019   Bartkoski et al. N/A N/A   10870018   122019   Bartkoski et al. N/A N/A   10870018   122009   Bartkoski et al. N/A N/A   10870018   122006   Fantini et al. N/A N/A   10909003744   122008   Fantini et al. N/A N/A   10090003310   122008   Failla et al. N/A N/A   200900033767   122009   Sparks et al. N/A N/A   201000177870   122009   Arnsoforf et al. N/A N/A   201000177871   122009   Arnsoforf et al. N/A N/A   201000177875   122009   Arnsoforf et al. N/A N/A   201000177876   122019   Arnsoforf et al. N/A N/A   201000177876   122019   Arnsoforf et al. N/A N/A   20100032748   122009   Arnsoforf et al. N/A N/A   20100032748   122009   Arnsoforf et al. N/A N/A   201000372786   122010   Brocken et al. N/A N/A   201000372786   122010   Brocken et al. N/A N/A   201100037218   122010   Brocken et al. N/A N/A   201100037218   122010   Brocken et al. N/A N/A   20110037218   122010   Brocken et al. N/A N/A   2012007756   122011   Melsner et al. N/A N/A   20120077576   122011   Melsner et al. N/A N/A   20130305975   122011   Shukla et al. N/A N/A   20140305976   122013   Dean et al. N/A N/A   20140705796   122013   Dean et al. N/A N/A   20140705796   122013   Dean et al. N/A N/A   20140705796   122014   Brooken et al. N/A N/A   201607030744   122015   Brocken et al. N/A N/A   201607030					
10315047   12/2018   Gillia et al.   N/A   N/A   10413755   12/2018   Gilmienius et al.   N/A   N/A   10413755   12/2018   Sahadevan   N/A   N/A   N/A   10449389   12/2018   Kussel et al.   N/A   N/A   N/A   10449389   12/2019   Kussel et al.   N/A   N/A   N/A   10452825   12/2019   Friedman   N/A   N/A   N/A   10525285   12/2019   Vanderstraten et al.   N/A   N/A   N/A   10603514   12/2019   Grittani et al.   N/A   N/A   N/A   10603514   12/2019   Rocken et al.   N/A   N/A   N/A   10603660   12/2019   Bertsche et al.   N/A   N/A   N/A   10635609   12/2019   Bertsche et al.   N/A   N/A   N/A   1066100   12/2019   Boyd et al.   N/A   N/A   N/A   10662528   12/2019   Hesee   N/A   N/A   N/A   10682528   12/2019   Hesee   N/A   N/A   N/A   N/A   10783746   12/2019   Kwak et al.   N/A   N/A   N/A   10783746   12/2019   Bartsoki et al.   N/A   N/A   N/A   10780746   12/2019   Bartsoki et al.   N/A   N/					
10413755   12/2018			Ollila et al.	N/A	N/A
10449389   12/2018	10315047	12/2018	Glimelius et al.	N/A	N/A
10485988   12/2019	10413755	12/2018			
105525285   12/2019					
10549117   12/2019					
10603514					
10636609   12/2019   Bertsche et al.   N/A   N/A   10660588   12/2019   Boryd et al.   N/A   N/A   10660588   12/2019   Shen   N/A   N/A   N/A   10660588   12/2019   Shen   N/A   N/A   N/A   10660528   12/2019   Shen   N/A   N/A   N/A   106062528   12/2019   Heese   N/A   N/A   N/A   107072716   12/2019   Heese   N/A   N/A   N/A   10870018   12/2019   Barkoski et al.   N/A   N/A   N/A   10870018   12/2019   Barkoski et al.   N/A   N/A   N/A   10870018   12/2019   Barkoski et al.   N/A   N/A   N/A   10870018   12/2006   Fantini et al.   N/A   N/A   N/A   10870018   12/2006   Fantini et al.   N/A   N/A   N/A   10909/0287467   12/2008   Failla et al.   N/A   N/A   N/A   10909/0287467   12/2008   Sparks et al.   N/A   N/A   N/A   101019032   12/2009   Yan et al.   N/A   N/A   N/A   1010/020317   12/2009   Amsdorf et al.   N/A   N/A   N/A   1010/020317   12/2009   Amsdorf et al.   N/A   N/A   N/A   1010/020317   12/2009   Bert et al.   N/A   N/A   N/A   1010/020317   12/2009   Bert et al.   N/A   N/A   N/A   1011/03058   12/2010   Yan et al.   N/A   N/A   N/A   1011/03058   12/2010   Yan et al.   N/A   N/A   N/A   1011/03058   12/2011   Yan et al.   N/A   N/A   N/A   1011/031593   12/2011   Yan et al.   N/A   N/A   N/A   1011/0316932   12/2011   Yan et al.   N/A   N/A   N/A   1011/03058   12/2011   Yan et al.   N/A   N/A   N/A   1011/0316932   12/2011   Yan et al.   N/A   N/A   N/A   1011/0306346   12/2011   Under the al.   N/A   N/A   N/A   1011/0306346   12/2011   Under the al.   N/A   N/A   N/A   1011/03063476   12/2011   Under the al.   N/A   N/A   N/A   1011/03063476   12/2013   Lewellen et al.   N/A   N/A   N/A   1011/03063476   12/2013   Lewellen et al.   N/A   N/A   N/A   1011/03063476   12/2013   Lewellen et al.   N/A   N/A   N/A   1011/03063476   12/2013   Dean et al.   N/A   N/A   N/A   1011/03063476   12/2014   Bharat et al.   N/A   N/A					
10636608					
10661100					
10882528   12/2019	10660588		Boyd et al.	N/A	
10702716	10661100	12/2019		N/A	N/A
10758746					
10870018					
2004/0227104					
2007/0287878   12/2006					
2008/0023644         12/2008         Failla et al.         N/A         N/A           2009/0087467         12/2008         Failla et al.         N/A         N/A           2010/019032         12/2009         Yan et al.         N/A         N/A           2010/017870         12/2009         Nord et al.         N/A         N/A           2010/0178245         12/2009         Arnsdorf et al.         N/A         N/A           2010/0327188         12/2009         Bert et al.         N/A         N/A           2011/03027188         12/2009         Bert et al.         N/A         N/A           2011/0035058         12/2010         Maltz et al.         N/A         N/A           2011/0135058         12/2010         Sgouros et al.         N/A         N/A           2012/0076271         12/2011         Yan et al.         N/A         N/A           2012/0157746         12/2011         Meltsner et al.         N/A         N/A           2012/0197058         12/2011         Meltsner et al.         N/A         N/A           2012/0197059         12/2011         Shukla et al.         N/A         N/A           2012/0197050         12/2012         Carlton et al.         N/A         N/A					
2009/0063110         12/2008         Failla et al.         N/A         N/A           2009/0287467         12/2009         Sparks et al.         N/A         N/A           2010/0119032         12/2009         Yan et al.         N/A         N/A           2010/0178745         12/2009         Nord et al.         N/A         N/A           2010/0260317         12/2009         Arnsdorf et al.         N/A         N/A           2011/0327188         12/2009         Bert et al.         N/A         N/A           2011/0091015         12/2010         Maltz et al.         N/A         N/A           2011/0091015         12/2010         Sgouros et al.         N/A         N/A           2011/0015508         12/2010         Sgouros et al.         N/A         N/A           2012/0076271         12/2011         Yan et al.         N/A         N/A           2012/0171745         12/2011         Meltsner et al.         N/A         N/A           2012/0197058         12/2011         Itoh         N/A         N/A           2013/0116929         12/2012         Carlton et al.         N/A         N/A           2013/0177641         12/2012         Butson et al.         N/A         N/A					
2009/0287467   12/2008   Sparks et al.   N/A   N/A   N/A   2010/0119032   12/2009   Yan et al.   N/A   N/A   N/A   N/A   N/A   2010/017870   12/2009   Arnsdorf et al.   N/A   N/A   N/A   N/A   2010/0260317   12/2009   Chang et al.   N/A   N/A   N/A   N/A   2010/0327188   12/2009   Bert et al.   N/A   N/A   N/A   2011/0006024   12/2010   Maltz et al.   N/A   N/A   N/A   2011/0006158   12/2010   Yu et al.   N/A   N/A   N/A   N/A   2011/0015058   12/2010   Sgouros et al.   N/A   N/A   N/A   2012/0076271   12/2011   Yan et al.   N/A   N/A   N/A   2012/0157746   12/2011   Meltsner et al.   N/A   N/A   N/A   2012/0157746   12/2011   Meltsner et al.   N/A   N/A   N/A   2012/0157746   12/2011   Shukla et al.   N/A   N/A   N/A   2012/0157058   12/2011   Shukla et al.   N/A   N/A   N/A   2013/0160929   12/2012   Garlton et al.   N/A   N/A   N/A   2013/0150922   12/2012   Butson et al.   N/A   N/A   N/A   2013/0231516   12/2012   Ghoroghchian   N/A   N/A   N/A   2013/0267756   12/2012   Totake   600/1   A61N 5/1048   2014/017807   12/2013   Lewellen et al.   N/A   N/A   N/A   2014/026926   12/2013   Li et al.   N/A   N/A   N/A   2014/026926   12/2013   Li et al.   N/A   N/A   N/A   2015/020464   12/2013   Dean et al.   N/A   N/A   N/A   2015/020464   12/2014   Bharat et al.   N/A   N/A   N/A   2015/0206855   12/2014   Bharat et al.   N/A   N/A   N/A   2015/020694   12/2015   Bharadwaj et al.   N/A   N/A   N/A   2016/0306423   12/2016   Sumanaweera et al.   N/A   N/A   N/A   2016/0310764   12/2015   Bharadwaj et al.   N/A   N/A   N/A   2016/0310764   12/2015   Sharadwaj et al.   N/A   N/A   N/A   2016/0310764   12/2016   Sumanaweera et al.   N/A   N/A   N/A   2016/0310764   12/2017   Papp et al.   N/A   N/A   N/A   2018/0099155   12/2017   Papp et al.   N/A   N/A   N/A   2018/0099155   12/2017   Papp et al.   N/A   N/A   2018/0099155   12/2017   Pricels et					
2010/0119032   12/2009					
2010/0177870   12/2009   Nord et al.   N/A   N/A   N/A   2010/0178245   12/2009   Arnsdorf et al.   N/A   N/A   N/A   2010/00260317   12/2009   Bert et al.   N/A   N/A   N/A   2010/0327188   12/2010   Bert et al.   N/A   N/A   N/A   2011/0006224   12/2010   Maltz et al.   N/A   N/A   N/A   N/A   2011/0035058   12/2010   Sgouros et al.   N/A   N/A   N/A   N/A   2011/0135058   12/2010   Sgouros et al.   N/A   N/A   N/A   N/A   2012/0076271   12/2011   Yan et al.   N/A   N/A   N/A   N/A   2012/0157746   12/2011   Meltsner et al.   N/A   N/A   N/A   N/A   2012/0197058   12/2011   Shukla et al.   N/A   N/A   N/A   N/A   2013/0116929   12/2012   Carlton et al.   N/A   N/A   N/A   N/A   2013/0150922   12/2012   Butson et al.   N/A   N/A   N/A   2013/0150922   12/2012   Ghoroghchian   N/A   N/A   N/A   2013/015766   12/2012   Loo et al.   N/A   N/A   N/A   2013/0237516   12/2012   Loo et al.   N/A   N/A   N/A   2013/0267756   12/2013   Lewellen et al.   N/A   N/A   N/A   2014/0185776   12/2013   Lewellen et al.   N/A   N/A   N/A   2014/026926   12/2013   La et al.   N/A   N/A   N/A   2014/026926   12/2013   Dean et al.   N/A   N/A   N/A   2014/026926   12/2013   Dean et al.   N/A   N/A   N/A   2015/0202464   12/2013   Dean et al.   N/A   N/A   N/A   2015/0202464   12/2014   Brand et al.   N/A   N/A   N/A   2015/0202464   12/2014   Brand et al.   N/A   N/A   N/A   2015/020344   12/2015   Schlosser   N/A   N/A   N/A   2016/0310764   12/2015   Schlosser   N/A   N/A   N/A   2016/0310764   12/2015   Schlosser   N/A   N/A   N/A   2017/0216622   12/2016   Dessy   N/A   N/A   N/A   2018/003159   12/2017   Jordan et al.   N/A   N/A   N/A   2018/003159   12/2017   Jordan et al.   N/A   N/A   N/A   2018/003159   12/2017   Jordan et al.   N/A   N/A   N/A   2018/0039159   12/2017   Jordan et al.   N/A   N/A   N/A   2018/0039159   12/2017   Schlosser   N/A   N/A   N/A					
2010/0178245   12/2009					
2010/0327188   12/2009   Bert et al.   N/A   N/A   N/A   2011/0006224   12/2010   Maltz et al.   N/A   N/A   N/A   2011/00091015   12/2010   Sgouros et al.   N/A   N/A   N/A   2011/0135058   12/2011   Yan et al.   N/A   N/A   N/A   2012/0076271   12/2011   Meltsner et al.   N/A   N/A   N/A   2012/0171745   12/2011   Itoh   N/A   N/A   N/A   2012/0197058   12/2011   Shukla et al.   N/A   N/A   N/A   2012/0197058   12/2011   Shukla et al.   N/A   N/A   N/A   2013/0116929   12/2012   Carlton et al.   N/A   N/A   N/A   2013/0150922   12/2012   Butson et al.   N/A   N/A   N/A   2013/0150922   12/2012   Ghoroghchian   N/A   N/A   N/A   2013/02371516   12/2012   Loo et al.   N/A   N/A   N/A   2013/023756   12/2012   Loo et al.   N/A   N/A   N/A   2014/0185776   12/2013   Lewellen et al.   N/A   N/A   N/A   2014/0206926   12/2013   Li et al.   N/A   N/A   N/A   2014/0206926   12/2013   La et al.   N/A   N/A   N/A   2014/0369476   12/2013   Dean et al.   N/A   N/A   N/A   2015/0202464   12/2014   Ereng   N/A   N/A   N/A   2015/0202464   12/2014   Brand et al.   N/A   N/A   N/A   2015/0203464   12/2014   Brand et al.   N/A   N/A   N/A   2015/0203464   12/2014   Brand et al.   N/A   N/A   N/A   2015/0203199   12/2016   Sumanaweera et al.   N/A   N/A   N/A   2016/0310764   12/2015   Schlosser   N/A   N/A   N/A   2017/0203129   12/2016   Sumanaweera et al.   N/A   N/A   N/A   2017/0203129   12/2016   Sumanaweera et al.   N/A   N/A   N/A   2018/0031594   12/2017   Papp et al.   N/A   N/A   N/A   2018/0031594   12/2017   Papp et al.   N/A   N/A   N/A   2018/0099155   12/2017   Pricels et al.   N/A   N/A   N/A   2018/0099159   12/2017   Pricels et al.   N/A   N/A   N/A   2018/0099159   12/2017   Pricels et al.   N/A   N/A   N/A   2018/0099159   12/2017   Pricels et al.   N/A   N/A   2018/0099159   12/2017   Pricels et al.   N/A   N/A   2018/0099159   12/2017   Pricels et al.   N/A   N/A   2018/0099159   12/2017   Carlton et al.   N/A   N/A   2018/0099159   12/2017   Carlton et al.   N/A   N/A   2018/0090159   12/2017   Carlt			Arnsdorf et al.		
2011/0006224         12/2010         Yu et al.         N/A         N/A           2011/0031058         12/2010         Yu et al.         N/A         N/A           2011/0135058         12/2010         Sgouros et al.         N/A         N/A           2012/0076271         12/2011         Yan et al.         N/A         N/A           2012/0157746         12/2011         Meltsner et al.         N/A         N/A           2012/0197058         12/2011         Shukla et al.         N/A         N/A           2013/0150929         12/2012         Garlton et al.         N/A         N/A           2013/0177641         12/2012         Ghoroghchian         N/A         N/A           2013/0231516         12/2012         Loo et al.         N/A         N/A           2014/0177807         12/2013         Lewellen et al.         N/A         N/A           2014/0185776         12/2013         Li et al.         N/A         N/A           2014/0266926         12/2013         van der Laarse         N/A         N/A           2014/0369476         12/2013         Dean et al.         N/A         N/A           2015/001817         12/2014         Feng         N/A         N/A	2010/0260317	12/2009	Chang et al.	N/A	N/A
2011/0091015         12/2010         Yu et al.         N/A         N/A           2011/00750571         12/2011         Yan et al.         N/A         N/A           2012/0075271         12/2011         Yan et al.         N/A         N/A           2012/0157746         12/2011         Meltsner et al.         N/A         N/A           2012/017745         12/2011         Itoh         N/A         N/A           2013/0116929         12/2012         Carlton et al.         N/A         N/A           2013/017641         12/2012         Ghoroghchian         N/A         N/A           2013/0231516         12/2012         Loo et al.         N/A         N/A           2013/0267756         12/2013         Lewellen et al.         N/A         N/A           2014/017807         12/2013         Lewellen et al.         N/A         N/A           2014/026926         12/2013         Li et al.         N/A         N/A           2014/026926         12/2013         Van der Laarse         N/A         N/A           2015/021817         12/2014         Feng         N/A         N/A           2015/0265855         12/2014         Brand et al.         N/A         N/A <td< td=""><td></td><td>12/2009</td><td>Bert et al.</td><td>N/A</td><td>N/A</td></td<>		12/2009	Bert et al.	N/A	N/A
2011/0135058         12/2010         Sgouros et al.         N/A         N/A           2012/0076271         12/2011         Yan et al.         N/A         N/A           2012/0157746         12/2011         Meltsner et al.         N/A         N/A           2012/0171745         12/2011         Itoh         N/A         N/A           2013/0116929         12/2012         Carlton et al.         N/A         N/A           2013/0150922         12/2012         Butson et al.         N/A         N/A           2013/0150922         12/2012         Ghoroghchian         N/A         N/A           2013/0267756         12/2012         Loo et al.         N/A         N/A           2013/0267756         12/2012         Loo et al.         N/A         N/A           2014/017807         12/2013         Lewellen et al.         N/A         N/A           2014/018576         12/2013         Li et al.         N/A         N/A           2014/0275706         12/2013         Van der Laarse         N/A         N/A           2014/026926         12/2013         Harding         N/A         N/A           2015/020244         12/2013         Harding         N/A         N/A           <		12/2010			
2012/0076271         12/2011         Yan et al.         N/A         N/A           2012/0157746         12/2011         Meltsner et al.         N/A         N/A           2012/017745         12/2011         Itoh         N/A         N/A           2012/0197058         12/2011         Shukla et al.         N/A         N/A           2013/0116929         12/2012         Butson et al.         N/A         N/A           2013/0150922         12/2012         Butson et al.         N/A         N/A           2013/017641         12/2012         Ghoroghchian         N/A         N/A           2013/0267756         12/2012         Totake         600/1         A61N 5/1048           2014/0177807         12/2013         Lewellen et al.         N/A         N/A           2014/026926         12/2013         Lewellen et al.         N/A         N/A           2014/026946         12/2013         Van der Laarse         N/A         N/A           2015/0202464         12/2013         Harding         N/A         N/A           2015/0202464         12/2014         Brand et al.         N/A         N/A           2015/0306423         12/2014         Bharad et al.         N/A         N/A					
2012/0157746         12/2011         Meltsner et al.         N/A         N/A           2012/0171745         12/2011         Itoh         N/A         N/A           2012/0197058         12/2011         Shukla et al.         N/A         N/A           2013/0116929         12/2012         Butson et al.         N/A         N/A           2013/0177641         12/2012         Ghoroghchian         N/A         N/A           2013/0231516         12/2012         Loo et al.         N/A         N/A           2013/0267756         12/2013         Lewellen et al.         N/A         N/A           2014/0185776         12/2013         Lewellen et al.         N/A         N/A           2014/0206926         12/2013         Le al.         N/A         N/A           2014/0206926         12/2013         van der Laarse         N/A         N/A           2014/026926         12/2013         Harding         N/A         N/A           2014/0369476         12/2013         Harding         N/A         N/A           2015/0202464         12/2014         Brand et al.         N/A         N/A           2015/0306423         12/2014         Bharat et al.         N/A         N/A					
2012/0171745         12/2011         Itoh         N/A         N/A           2012/0197058         12/2011         Shukla et al.         N/A         N/A           2013/0116929         12/2012         Carlton et al.         N/A         N/A           2013/0150922         12/2012         Butson et al.         N/A         N/A           2013/0277641         12/2012         Loo et al.         N/A         N/A           2013/0267756         12/2012         Loo et al.         N/A         N/A           2014/0177807         12/2013         Lewellen et al.         N/A         N/A           2014/026926         12/2013         Li et al.         N/A         N/A           2014/026926         12/2013         van der Laarse         N/A         N/A           2014/0275706         12/2013         Dean et al.         N/A         N/A           2014/0275706         12/2013         Harding         N/A         N/A           2015/0011817         12/2014         Feng         N/A         N/A           2015/0202464         12/2014         Brand et al.         N/A         N/A           2015/0306423         12/2014         Bharad et al.         N/A         N/A					
2012/0197058         12/2011         Shukla et al.         N/A         N/A           2013/0116929         12/2012         Carlton et al.         N/A         N/A           2013/0150922         12/2012         Butson et al.         N/A         N/A           2013/0177641         12/2012         Loo et al.         N/A         N/A           2013/0231516         12/2012         Loo et al.         N/A         N/A           2013/0267756         12/2013         Lewellen et al.         N/A         N/A           2014/0177807         12/2013         Lewellen et al.         N/A         N/A           2014/026926         12/2013         Lewellen et al.         N/A         N/A           2014/026926         12/2013         Van der Laarse         N/A         N/A           2014/026926         12/2013         Dean et al.         N/A         N/A           2014/0369476         12/2013         Harding         N/A         N/A           2015/0202464         12/2014         Brand et al.         N/A         N/A           2015/0202464         12/2014         Bharat et al.         N/A         N/A           2015/0306423         12/2014         Bharat et al.         N/A         N/A </td <td></td> <td></td> <td></td> <td></td> <td></td>					
2013/0116929         12/2012         Carlton et al.         N/A         N/A           2013/0150922         12/2012         Butson et al.         N/A         N/A           2013/0177641         12/2012         Ghoroghchian         N/A         N/A           2013/0231516         12/2012         Loo et al.         N/A         N/A           2013/0267756         12/2013         Lewellen et al.         N/A         N/A           2014/0177807         12/2013         Lewellen et al.         N/A         N/A           2014/026966         12/2013         La et al.         N/A         N/A           2014/026966         12/2013         van der Laarse         N/A         N/A           2014/026966         12/2013         van der Laarse         N/A         N/A           2014/026946         12/2013         Dean et al.         N/A         N/A           2014/0369476         12/2013         Harding         N/A         N/A           2015/021817         12/2014         Feng         N/A         N/A           2015/026955         12/2014         Brand et al.         N/A         N/A           2015/026940         12/2014         Bharadwaj et al.         N/A         N/A					
2013/0150922         12/2012         Butson et al.         N/A         N/A           2013/0177641         12/2012         Ghoroghchian         N/A         N/A           2013/0231516         12/2012         Loo et al.         N/A         N/A           2013/0267756         12/2012         Totake         600/1         A61N 5/1048           2014/017807         12/2013         Lewellen et al.         N/A         N/A           2014/026926         12/2013         Li et al.         N/A         N/A           2014/0275706         12/2013         Dean et al.         N/A         N/A           2014/0369476         12/2013         Harding         N/A         N/A           2015/0011817         12/2013         Harding         N/A         N/A           2015/0202464         12/2014         Feng         N/A         N/A           2015/0306423         12/2014         Bharad et al.         N/A         N/A           2016/0279444         12/2015         Schlosser         N/A         N/A           2017/0189721         12/2016         Sumanaweera et al.         N/A         N/A           2017/028193         12/2016         Peissy         N/A         N/A					
2013/0177641         12/2012         Ghoroghchian         N/A         N/A           2013/0231516         12/2012         Loo et al.         N/A         N/A           2013/0267756         12/2012         Totake         600/1         A61N 5/1048           2014/0177807         12/2013         Lewellen et al.         N/A         N/A           2014/0185776         12/2013         Li et al.         N/A         N/A           2014/0275706         12/2013         Dean et al.         N/A         N/A           2014/0369476         12/2013         Harding         N/A         N/A           2015/0011817         12/2014         Feng         N/A         N/A           2015/0202464         12/2014         Brand et al.         N/A         N/A           2015/0306423         12/2014         Bharat et al.         N/A         N/A           2016/0279444         12/2015         Schlosser         N/A         N/A           2016/0310764         12/2016         Sumanaweera et al.         N/A         N/A           2017/0189721         12/2016         Dessy         N/A         N/A           2017/0281973         12/2016         Pijtiaka et al.         N/A         N/A					
2013/0231516         12/2012         Loo et al.         N/A         N/A           2013/0267756         12/2012         Totake         600/1         A61N 5/1048           2014/0177807         12/2013         Lewellen et al.         N/A         N/A           2014/0206926         12/2013         Li et al.         N/A         N/A           2014/0205706         12/2013         Dean et al.         N/A         N/A           2014/0369476         12/2013         Harding         N/A         N/A           2015/0011817         12/2014         Feng         N/A         N/A           2015/0202464         12/2014         Brand et al.         N/A         N/A           2015/0306423         12/2014         Bharat et al.         N/A         N/A           2015/0306423         12/2014         Bharat et al.         N/A         N/A           2016/0279444         12/2015         Schlosser         N/A         N/A           2017/0189721         12/2016         Sumanaweera et al.         N/A         N/A           2017/023129         12/2016         Dessy         N/A         N/A           2017/0281973         12/2016         Fujitaka et al.         N/A         N/A					
2014/0177807         12/2013         Lewellen et al.         N/A         N/A           2014/0185776         12/2013         Li et al.         N/A         N/A           2014/0206926         12/2013         van der Laarse         N/A         N/A           2014/0275706         12/2013         Dean et al.         N/A         N/A           2014/0369476         12/2013         Harding         N/A         N/A           2015/031817         12/2014         Feng         N/A         N/A           2015/0202464         12/2014         Brand et al.         N/A         N/A           2015/0205855         12/2014         Bharad et al.         N/A         N/A           2015/0306423         12/2014         Bharat et al.         N/A         N/A           2016/0279444         12/2015         Schlosser         N/A         N/A           2016/0310764         12/2015         Bharadwaj et al.         N/A         N/A           2017/0189721         12/2016         Sumanaweera et al.         N/A         N/A           2017/0216622         12/2016         Dessy         N/A         N/A           2017/0218973         12/2016         Fujitaka et al.         N/A         N/A					
2014/0185776         12/2013         Li et al.         N/A         N/A           2014/0206926         12/2013         van der Laarse         N/A         N/A           2014/0275706         12/2013         Dean et al.         N/A         N/A           2014/0369476         12/2013         Harding         N/A         N/A           2015/0011817         12/2014         Feng         N/A         N/A           2015/0202464         12/2014         Brand et al.         N/A         N/A           2015/0306423         12/2014         Bharat et al.         N/A         N/A           2016/0279444         12/2015         Schlosser         N/A         N/A           2016/0310764         12/2015         Bharadwaj et al.         N/A         N/A           2017/0189721         12/2016         Sumanaweera et al.         N/A         N/A           2017/0203129         12/2016         Dessy         N/A         N/A           2017/0281973         12/2016         Fujitaka et al.         N/A         N/A           2018/0021594         12/2017         Papp et al.         N/A         N/A           2018/003183         12/2017         Prieels         N/A         N/A           <	2013/0267756	12/2012	Totake	600/1	A61N 5/1048
2014/0206926         12/2013         van der Laarse         N/A         N/A           2014/0275706         12/2013         Dean et al.         N/A         N/A           2014/0369476         12/2013         Harding         N/A         N/A           2015/0011817         12/2014         Feng         N/A         N/A           2015/0202464         12/2014         Brand et al.         N/A         N/A           2015/0306423         12/2014         Bharat et al.         N/A         N/A           2016/0279444         12/2015         Schlosser         N/A         N/A           2016/0310764         12/2015         Schlosser         N/A         N/A           2017/0189721         12/2015         Bharadwaj et al.         N/A         N/A           2017/02803129         12/2016         Dessy         N/A         N/A           2017/0281973         12/2016         Fujitaka et al.         N/A         N/A           2018/0021594         12/2017         Papp et al.         N/A         N/A           2018/0021594         12/2017         Papp et al.         N/A         N/A           2018/0091594         12/2017         Jordan et al.         N/A         N/A	2014/0177807	12/2013			
2014/0275706         12/2013         Dean et al.         N/A         N/A           2014/0369476         12/2013         Harding         N/A         N/A           2015/0011817         12/2014         Feng         N/A         N/A           2015/0202464         12/2014         Brand et al.         N/A         N/A           2015/0306423         12/2014         Bharat et al.         N/A         N/A           2016/0279444         12/2015         Schlosser         N/A         N/A           2016/0310764         12/2015         Bharadwaj et al.         N/A         N/A           2017/0189721         12/2016         Sumanaweera et al.         N/A         N/A           2017/0203129         12/2016         Dessy         N/A         N/A           2017/0216622         12/2016         Fujitaka et al.         N/A         N/A           2018/021594         12/2017         Papp et al.         N/A         N/A           2018/0021594         12/2017         Papp et al.         N/A         N/A           2018/0056090         12/2017         Jordan et al.         N/A         N/A           2018/0099154         12/2017         Prieels         N/A         N/A					
2014/0369476         12/2013         Harding         N/A         N/A           2015/0011817         12/2014         Feng         N/A         N/A           2015/0202464         12/2014         Brand et al.         N/A         N/A           2015/0265855         12/2014         Bharat et al.         N/A         N/A           2015/0306423         12/2014         Bharat et al.         N/A         N/A           2016/0279444         12/2015         Schlosser         N/A         N/A           2016/0310764         12/2015         Bharadwaj et al.         N/A         N/A           2017/0189721         12/2016         Sumanaweera et al.         N/A         N/A           2017/0203129         12/2016         Dessy         N/A         N/A           2017/0216622         12/2016         Fujitaka et al.         N/A         N/A           2018/0281973         12/2016         Allen et al.         N/A         N/A           2018/0021594         12/2017         Papp et al.         N/A         N/A           2018/0043183         12/2017         Jordan et al.         N/A         N/A           2018/0099154         12/2017         Prieels         N/A         N/A					
2015/0011817         12/2014         Feng         N/A         N/A           2015/0202464         12/2014         Brand et al.         N/A         N/A           2015/0265855         12/2014         Tachikawa         600/1         A61N 5/1048           2015/0306423         12/2014         Bharat et al.         N/A         N/A           2016/0279444         12/2015         Schlosser         N/A         N/A           2016/0310764         12/2015         Bharadwaj et al.         N/A         N/A           2017/0189721         12/2016         Sumanaweera et al.         N/A         N/A           2017/0203129         12/2016         Dessy         N/A         N/A           2017/0216622         12/2016         Fujitaka et al.         N/A         N/A           2017/0281973         12/2016         Allen et al.         N/A         N/A           2018/0021594         12/2017         Papp et al.         N/A         N/A           2018/0043183         12/2017         Sheng et al.         N/A         N/A           2018/0099154         12/2017         Prieels         N/A         N/A           2018/0099155         12/2017         Prieels et al.         N/A         N/A					
2015/0202464         12/2014         Brand et al.         N/A         N/A           2015/0265855         12/2014         Tachikawa         600/1         A61N 5/1048           2015/0306423         12/2014         Bharat et al.         N/A         N/A           2016/0279444         12/2015         Schlosser         N/A         N/A           2016/0310764         12/2015         Bharadwaj et al.         N/A         N/A           2017/0189721         12/2016         Sumanaweera et al.         N/A         N/A           2017/0203129         12/2016         Dessy         N/A         N/A           2017/0216622         12/2016         Fujitaka et al.         N/A         N/A           2017/0281973         12/2016         Allen et al.         N/A         N/A           2018/0021594         12/2017         Papp et al.         N/A         N/A           2018/0043183         12/2017         Sheng et al.         N/A         N/A           2018/0099154         12/2017         Prieels         N/A         N/A           2018/0099155         12/2017         Prieels et al.         N/A         N/A           2018/0197303         12/2017         Sahadevan         N/A         N/A </td <td></td> <td></td> <td></td> <td></td> <td></td>					
2015/0265855         12/2014         Tachikawa         600/1         A61N 5/1048           2015/0306423         12/2014         Bharat et al.         N/A         N/A           2016/0279444         12/2015         Schlosser         N/A         N/A           2016/0310764         12/2015         Bharadwaj et al.         N/A         N/A           2017/0189721         12/2016         Sumanaweera et al.         N/A         N/A           2017/0203129         12/2016         Dessy         N/A         N/A           2017/0216622         12/2016         Fujitaka et al.         N/A         N/A           2018/021594         12/2016         Allen et al.         N/A         N/A           2018/0021594         12/2017         Papp et al.         N/A         N/A           2018/0043183         12/2017         Sheng et al.         N/A         N/A           2018/0056090         12/2017         Jordan et al.         N/A         N/A           2018/0099154         12/2017         Prieels         N/A         N/A           2018/0099155         12/2017         Forton et al.         N/A         N/A           2018/0197303         12/2017         Sahadevan         N/A         N/A <td></td> <td></td> <td></td> <td></td> <td></td>					
2015/0306423       12/2014       Bharat et al.       N/A       N/A         2016/0279444       12/2015       Schlosser       N/A       N/A         2016/0310764       12/2015       Bharadwaj et al.       N/A       N/A         2017/0189721       12/2016       Sumanaweera et al.       N/A       N/A         2017/0203129       12/2016       Dessy       N/A       N/A         2017/0216622       12/2016       Fujitaka et al.       N/A       N/A         2018/021594       12/2016       Allen et al.       N/A       N/A         2018/0021594       12/2017       Papp et al.       N/A       N/A         2018/0043183       12/2017       Sheng et al.       N/A       N/A         2018/0056090       12/2017       Jordan et al.       N/A       N/A         2018/0099154       12/2017       Prieels       N/A       N/A         2018/0099155       12/2017       Forton et al.       N/A       N/A         2018/0154183       12/2017       Sahadevan       N/A       N/A         2018/0207425       12/2017       Carlton et al.       N/A       N/A         2018/0236268       12/2017       Zwart et al.       N/A       N/A </td <td></td> <td></td> <td></td> <td></td> <td></td>					
2016/0279444         12/2015         Schlosser         N/A         N/A           2016/0310764         12/2015         Bharadwaj et al.         N/A         N/A           2017/0189721         12/2016         Sumanaweera et al.         N/A         N/A           2017/0203129         12/2016         Dessy         N/A         N/A           2017/0216622         12/2016         Fujitaka et al.         N/A         N/A           2018/021594         12/2016         Allen et al.         N/A         N/A           2018/0021594         12/2017         Papp et al.         N/A         N/A           2018/0043183         12/2017         Sheng et al.         N/A         N/A           2018/0056090         12/2017         Jordan et al.         N/A         N/A           2018/0099154         12/2017         Prieels         N/A         N/A           2018/0099155         12/2017         Prieels et al.         N/A         N/A           2018/0099159         12/2017         Forton et al.         N/A         N/A           2018/0197303         12/2017         Jordan et al.         N/A         N/A           2018/0207425         12/2017         Carlton et al.         N/A         N/A <td></td> <td></td> <td></td> <td></td> <td></td>					
2016/0310764       12/2015       Bharadwaj et al.       N/A       N/A         2017/0189721       12/2016       Sumanaweera et al.       N/A       N/A         2017/0203129       12/2016       Dessy       N/A       N/A         2017/0216622       12/2016       Fujitaka et al.       N/A       N/A         2017/0281973       12/2016       Allen et al.       N/A       N/A         2018/0021594       12/2017       Papp et al.       N/A       N/A         2018/0043183       12/2017       Sheng et al.       N/A       N/A         2018/0056090       12/2017       Jordan et al.       N/A       N/A         2018/0099154       12/2017       Prieels       N/A       N/A         2018/0099155       12/2017       Prieels et al.       N/A       N/A         2018/0099159       12/2017       Forton et al.       N/A       N/A         2018/0154183       12/2017       Sahadevan       N/A       N/A         2018/0207425       12/2017       Carlton et al.       N/A       N/A         2018/0236268       12/2017       Zwart et al.       N/A       N/A         2019/0022407       12/2018       Abel et al.       N/A       N/A					
2017/0189721       12/2016       Sumanaweera et al.       N/A       N/A         2017/0203129       12/2016       Dessy       N/A       N/A         2017/0216622       12/2016       Fujitaka et al.       N/A       N/A         2017/0281973       12/2016       Allen et al.       N/A       N/A         2018/0021594       12/2017       Papp et al.       N/A       N/A         2018/0043183       12/2017       Sheng et al.       N/A       N/A         2018/0056090       12/2017       Jordan et al.       N/A       N/A         2018/0099154       12/2017       Prieels       N/A       N/A         2018/0099155       12/2017       Prieels et al.       N/A       N/A         2018/0099159       12/2017       Forton et al.       N/A       N/A         2018/0154183       12/2017       Sahadevan       N/A       N/A         2018/0207425       12/2017       Carlton et al.       N/A       N/A         2018/0236268       12/2017       Zwart et al.       N/A       N/A         2019/0022407       12/2018       Abel et al.       N/A       N/A					
2017/0216622       12/2016       Fujitaka et al.       N/A       N/A         2017/0281973       12/2016       Allen et al.       N/A       N/A         2018/0021594       12/2017       Papp et al.       N/A       N/A         2018/0043183       12/2017       Sheng et al.       N/A       N/A         2018/0056090       12/2017       Jordan et al.       N/A       N/A         2018/0099154       12/2017       Prieels       N/A       N/A         2018/0099155       12/2017       Prieels et al.       N/A       N/A         2018/0099159       12/2017       Forton et al.       N/A       N/A         2018/0154183       12/2017       Sahadevan       N/A       N/A         2018/0207425       12/2017       Jordan et al.       N/A       N/A         2018/0236268       12/2017       Carlton et al.       N/A       N/A         2019/0022407       12/2018       Abel et al.       N/A       N/A	2017/0189721	12/2016		N/A	N/A
2017/0281973       12/2016       Allen et al.       N/A       N/A         2018/0021594       12/2017       Papp et al.       N/A       N/A         2018/0043183       12/2017       Sheng et al.       N/A       N/A         2018/0056090       12/2017       Jordan et al.       N/A       N/A         2018/0099154       12/2017       Prieels       N/A       N/A         2018/0099155       12/2017       Prieels et al.       N/A       N/A         2018/0099159       12/2017       Forton et al.       N/A       N/A         2018/0154183       12/2017       Sahadevan       N/A       N/A         2018/0197303       12/2017       Jordan et al.       N/A       N/A         2018/0207425       12/2017       Carlton et al.       N/A       N/A         2018/0236268       12/2017       Zwart et al.       N/A       N/A         2019/0022407       12/2018       Abel et al.       N/A       N/A	2017/0203129	12/2016	Dessy	N/A	N/A
2018/0021594       12/2017       Papp et al.       N/A       N/A         2018/0043183       12/2017       Sheng et al.       N/A       N/A         2018/0056090       12/2017       Jordan et al.       N/A       N/A         2018/0099154       12/2017       Prieels       N/A       N/A         2018/0099155       12/2017       Prieels et al.       N/A       N/A         2018/0099159       12/2017       Forton et al.       N/A       N/A         2018/0154183       12/2017       Sahadevan       N/A       N/A         2018/0197303       12/2017       Jordan et al.       N/A       N/A         2018/0207425       12/2017       Carlton et al.       N/A       N/A         2018/0236268       12/2017       Zwart et al.       N/A       N/A         2019/0022407       12/2018       Abel et al.       N/A       N/A	2017/0216622	12/2016		N/A	
2018/0043183       12/2017       Sheng et al.       N/A       N/A         2018/0056090       12/2017       Jordan et al.       N/A       N/A         2018/0099154       12/2017       Prieels       N/A       N/A         2018/0099155       12/2017       Prieels et al.       N/A       N/A         2018/0099159       12/2017       Forton et al.       N/A       N/A         2018/0154183       12/2017       Sahadevan       N/A       N/A         2018/0197303       12/2017       Jordan et al.       N/A       N/A         2018/0207425       12/2017       Carlton et al.       N/A       N/A         2018/0236268       12/2017       Zwart et al.       N/A       N/A         2019/0022407       12/2018       Abel et al.       N/A       N/A					
2018/0056090       12/2017       Jordan et al.       N/A       N/A         2018/0099154       12/2017       Prieels       N/A       N/A         2018/0099155       12/2017       Prieels et al.       N/A       N/A         2018/0099159       12/2017       Forton et al.       N/A       N/A         2018/0154183       12/2017       Sahadevan       N/A       N/A         2018/0197303       12/2017       Jordan et al.       N/A       N/A         2018/0207425       12/2017       Carlton et al.       N/A       N/A         2018/0236268       12/2017       Zwart et al.       N/A       N/A         2019/0022407       12/2018       Abel et al.       N/A       N/A					
2018/0099154       12/2017       Prieels       N/A       N/A         2018/0099155       12/2017       Prieels et al.       N/A       N/A         2018/0099159       12/2017       Forton et al.       N/A       N/A         2018/0154183       12/2017       Sahadevan       N/A       N/A         2018/0197303       12/2017       Jordan et al.       N/A       N/A         2018/0207425       12/2017       Carlton et al.       N/A       N/A         2018/0236268       12/2017       Zwart et al.       N/A       N/A         2019/0022407       12/2018       Abel et al.       N/A       N/A					
2018/0099155       12/2017       Prieels et al.       N/A       N/A         2018/0099159       12/2017       Forton et al.       N/A       N/A         2018/0154183       12/2017       Sahadevan       N/A       N/A         2018/0197303       12/2017       Jordan et al.       N/A       N/A         2018/0207425       12/2017       Carlton et al.       N/A       N/A         2018/0236268       12/2017       Zwart et al.       N/A       N/A         2019/0022407       12/2018       Abel et al.       N/A       N/A					
2018/0099159       12/2017       Forton et al.       N/A       N/A         2018/0154183       12/2017       Sahadevan       N/A       N/A         2018/0197303       12/2017       Jordan et al.       N/A       N/A         2018/0207425       12/2017       Carlton et al.       N/A       N/A         2018/0236268       12/2017       Zwart et al.       N/A       N/A         2019/0022407       12/2018       Abel et al.       N/A       N/A					
2018/0154183       12/2017       Sahadevan       N/A       N/A         2018/0197303       12/2017       Jordan et al.       N/A       N/A         2018/0207425       12/2017       Carlton et al.       N/A       N/A         2018/0236268       12/2017       Zwart et al.       N/A       N/A         2019/0022407       12/2018       Abel et al.       N/A       N/A					
2018/0197303       12/2017       Jordan et al.       N/A       N/A         2018/0207425       12/2017       Carlton et al.       N/A       N/A         2018/0236268       12/2017       Zwart et al.       N/A       N/A         2019/0022407       12/2018       Abel et al.       N/A       N/A					
2018/0207425       12/2017       Carlton et al.       N/A       N/A         2018/0236268       12/2017       Zwart et al.       N/A       N/A         2019/0022407       12/2018       Abel et al.       N/A       N/A					
2018/0236268       12/2017       Zwart et al.       N/A       N/A         2019/0022407       12/2018       Abel et al.       N/A       N/A					
2019/0022422 12/2018 Trail et al. N/A N/A					
	2019/0022422	12/2018	Trail et al.	N/A	N/A

2019/0054315	12/2018	Isola et al.	N/A	N/A
2019/0070435	12/2018	Joe Anto et al.	N/A	N/A
2019/0168027	12/2018	Smith et al.	N/A	N/A
2019/0255361	12/2018	Mansfield	N/A	N/A
2019/0299027	12/2018	Fujii et al.	N/A	N/A
2019/0299029	12/2018	Inoue	N/A	N/A
2019/0351259	12/2018	Lee et al.	N/A	N/A
2020/0001118	12/2019	Snider, III et al.	N/A	N/A
2020/0022248	12/2019	Yi et al.	N/A	N/A
2020/0030633	12/2019	Van Heteren et al.	N/A	N/A
2020/0035438	12/2019	Star-Lack et al.	N/A	N/A
2020/0069818	12/2019	Jaskula-Ranga et al.	N/A	N/A
2020/0164224	12/2019	Vanderstraten et al.	N/A	N/A
2020/0178890	12/2019	Otto	N/A	N/A
2020/0197730	12/2019	Safavi-Naeini et al.	N/A	N/A
2020/0254279	12/2019	Ohishi	N/A	N/A
2020/0269068	12/2019	Abel et al.	N/A	N/A
2020/0276456	12/2019	Swerdloff	N/A	N/A
2020/0282234	12/2019	Folkerts et al.	N/A	N/A
2020/0298025	12/2019	Cooley, III	N/A	A61N 5/1079

## FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
104001270	12/2013	CN	N/A
106730407	12/2016	CN	N/A
107362464	12/2016	CN	N/A
109966662	12/2018	CN	N/A
111481840	12/2019	CN	N/A
111481841	12/2019	CN	N/A
010207	12/2007	EA	N/A
0979656	12/1999	EP	N/A
2510978	12/2011	EP	N/A
3178522	12/2016	EP	N/A
3338858	12/2017	EP	N/A
3384961	12/2017	EP	N/A
3421087	12/2018	EP	N/A
3453427	12/2018	EP	N/A
3586920	12/2019	EP	N/A
2617283	12/1996	JP	N/A
2019097969	12/2018	JP	N/A
2007017177	12/2006	WO	N/A
2010018476	12/2009	WO	N/A
2013081218	12/2012	WO	N/A
2013133936	12/2012	WO	N/A
2014139493	12/2013	WO	N/A
2015038832	12/2014	WO	N/A
2015102680	12/2014	WO	N/A
2016122957	12/2015	WO	N/A
2017156316	12/2016	WO	N/A
2017156419	12/2016	WO	N/A
2017174643	12/2016	WO	N/A
2018137772	12/2017	WO	N/A
2018152302	12/2017	WO	N/A
2019097250	12/2018	WO	N/A
2019103983	12/2018	WO	N/A
2019164835	12/2018	WO	N/A
2019166702	12/2018	WO	N/A
2019185378	12/2018	WO	N/A
2019222436	12/2018	WO	N/A
2020018904	12/2019	WO	N/A
2020064832	12/2019	WO	N/A
2020107121	12/2019	WO	N/A
2020159360	12/2019	WO	N/A
OTHER BURL	CATIONS		

# OTHER PUBLICATIONS

M. McManus et al., "The challenge of ionisation chamber dosimetry in ultra-short pulsed high dose-rate Very High Energy Electron beams," Sci Rep 10, 9089 Jun. 3, 2020, https://doi.org/10.1038/s41598-020-65819-y. cited by applicant

Ibrahim Oraiqat et al., "An Ionizing Radiation Acoustic Imaging (iRAI) Technique for Real-Time Dosimetric Measurements for FLASH Radiotherapy," Medi Issue 10, Oct. 2020, pp. 5090-5101, First published: Jun. 27, 2020, https://doi.org/10.1002/mp.14358. cited by applicant

K. Petersson et al., "Dosimetry of ultra high dose rate irradiation for studies on the biological effect induced in normal brain and GBM," ICTR-PHE 2016, p. 8 https://publisher-

connector.core.ac.uk/resourcesync/data/elsevier/pdf/14c/aHROcDovL2FwaS5lbHNIdmllci5jb20vY29udGVudC9hcnRpY2xIL3BpaS9zMDE2NzgxNDAxNjl

Susanne Auer et al., "Survival of tumor cells after proton irradiation with ultra-high dose rates," Radiation Oncology 2011, 6:139, Published Oct. 18, 2011, Dohttps://doi.org/10.1186/1748-717X-6-139. cited by applicant

Cynthia E. Keen, "Clinical linear accelerator delivers FLASH radiotherapy," Physics World, Apr. 23, 2019, IOP Publishing Ltd, https://physicsworld.com/a/cl

accelerator-delivers-flash-radiotherapy/. cited by applicant

Fan et al., "Emission guided radiation therapy for lung and prostate cancers: A feasibility study on a digital patient," Med Phys. Nov. 2012; 39(11): 7140-7152 Nov. 5, 2012. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505203/ doi: 10.1118/1.4761951. cited by applicant

Favaudon et al., "Ultrahigh dose-rate, "flash" irradiation minimizes the side-effects of radiotherapy," Cancer / Radiotherapy, vol. 19, Issues 6-7, Oct. 2015, p Available online Aug. 12, 2015, https://doi.org/10.1016/j.canrad.2015.04.006. cited by applicant

O. Zlobinskaya et al., "The Effects of Ultra-High Dose Rate Proton Irradiation on Growth Delay in the Treatment of Human Tumor Xenografts in Nude Mice Research, 181(2):177-183. Published Feb. 13, 2014, DOI: http://dx.doi.org/10.1667/RR13464.1. cited by applicant

Bjorn Zackrisson, "Biological Effects Of High Energy Radiation And Ultra High Dose Rates," UMEA University Medical Dissertations, New series No. 315-From the Department of Oncology, University of Umea, Umea, Sweden, ISBN 91-7174-614-5, Printed in Sweden by the Printing Office of Umea University, by applicant

P. Montay-Gruel et al., "Irradiation in a flash: Unique sparing of memory in mice after whole brain irradiation with dose rates above 100 Gy/s," Radiotherapy 124, Issue 3, Sep. 2017, pp. 365-369, Available online May 22, 2017, doi: 10.1016/j.radonc.2017.05.003. cited by applicant

BW Loo et al., "Delivery of Ultra-Rapid Flash Radiation Therapy and Demonstration of Normal Tissue Sparing After Abdominal Irradiation of Mice," International Control of Mice, "International Control of Mice," International Control of Mice, "International

https://doi.org/10.1016/j.ijrobp.2017.02.101. cited by applicant

Bhanu Prasad Venkatesulu et al., "Ultra high dose rate (35 Gy/sec) radiation does not spare the normal tissue In cardiac and splenic models of lymphopenia ar syndrome," Sci Rep 9, 17180 (2019), Published Nov. 20, 2019, DOI: https://doi.org/10.1038/s41598-019-53562-y. cited by applicant

P. Montay-Gruel et al., "Long-term neurocognitive benefits of FLASH radiotherapy driven by reduced reactive oxygen species," PNAS May 28, 2019, vol. 11 10943-10951; first published May 16, 2019, https://doi.org/10.1073/pnas.1901777116. cited by applicant

Peter G. Maxim et al., "FLASH radiotherapy: Newsflash or flash in the pan?", Medical Physics, 46 (10), Oct. 2019, pp. 4287-4290, American Association of Medicine, First published: Jun. 27, 2019, https://doi.org/10.1002/mp.13685. cited by applicant

Andrei Pugachev et al., "Pseudo beam's-eye-view as applied to beam orientation selection in intensity-modulated radiation therapy," Int. J. Radiation Oncolog 51, Issue 5, p. 1361-1370, Dec. 1, 2001, DOI: https://doi.org/10.1016/S0360-3016(01)01736-9. cited by applicant

Xiaodong Zhang et al., "Intensity-Modulated Proton Therapy Reduces the Dose to Normal Tissue Compared With Intensity-Modulated Radiation Therapy or Proton Therapy and Enables Individualized Radical Radiotherapy for Extensive Stage IIIB Non-Small-Cell Lung Cancer: A Virtual Clinical Study," Int. J. Rad Biol. Phys., vol. 77, No. 2, pp. 357-366, 2010, Available online Aug. 5, 2009, DOI: https://doi.org/10.1016/j.ijrobp.2009.04.028. cited by applicant

A. J. Lomax et al., "Intensity modulated proton therapy: A clinical example," Medical Physics, vol. 28, Issue 3, Mar. 2001, pp. 317-324, First published: Mar. https://doi.org/10.1118/1.1350587. cited by applicant

Lamberto Widesott et al., "Intensity-Modulated Proton Therapy Versus Helical Tomotherapy in Nasopharynx Cancer: Planning Comparison and NTCP Evaluation Oncology Biol. Phys., vol. 72, No. 2, pp. 589-596, Oct. 1, 2008, Available online Sep. 13, 2008, DOI: https://doi.org/10.1016/j.ijrobp.2008.05.065. Andrei Pugachev et al., "Role of beam orientation optimization in intensity-modulated radiation therapy," Int. J. Radiation Oncology Biol. Phys., vol. 50, No. 1, 2001, Available online May 10, 2001, DOI: https://doi.org/10.1016/S0360-3016(01)01502-4. cited by applicant

Damien C. Weber et al., "Radiation therapy planning with photons and protons for early and advanced breast cancer: an overview," Radiat Oncol. 2006; 1: 22 Jul. 20, 2006, doi: 10.1186/1748-717X-1-22. cited by applicant

Jul. 20, 2006, doi: 10.1186/1748-717X-1-22. cited by applicant RaySearch Laboratories, "Leading the way in cancer treatment, Annual Report 2013," RaySearch Laboratories (publ), Stockholm, Sweden, 94 pages, Apr. 20

https://www.raysearchlabs.com/siteassets/about-overview/media-center/wp-re-ev-n-pdfs/brochures/raysearch-ar-2013-eng.pdf. cited by applicant Fredrik Carlsson, "Utilizing Problem Structure in Optimization of Radiation Therapy," KTH Engineering Sciences, Doctoral Thesis, Stockholm, Sweden, Apr

Optimization and Systems Theory, Department of Mathematics, Royal Institute of Technology, Stockholm, Sweden, ISSN 1401-2294, https://www.raysearchlabs.com/globalassets/about-overview/media-center/wp-re-ev-n-pdfs/publications/thesis-fredrik\_light.pdf. cited by applicant

Chang-Ming Charlie Ma, "Physics and Dosimetric Principles of SRS and SBRT," Mathews J Cancer Sci. 4(2): 22, 2019, published: Dec. 11, 2019, ISSN: 247

https://doi.org/10.30654/MJCS.10022. cited by applicant
Alterego-Admin, "Conventional Radiation Therapy May Not Protect Healthy Brain Cells," International Neuropsychiatric Association—INA, Oct. 10, 2019,

https://inawebsite.org/conventional-radiation-therapy-may-not-protect-healthy-brain-cells/. cited by applicant
Schell Stefan et al., "Advanced treatment planning methods for efficient radiation therapy with laser accelarated proton and ion beams", Medical Physics, AIF

vol. 37, No. 10, Sep. 20, 2010 (Sep. 20, 2010), pp. 5330-5340. cited by applicant
Aafke Christine Kraan, "Range verification methods in particle therapy: underlying physics and Monte Carlo modeling," Frontiers in Oncology, Jul. 7, 2015

27 pages, doi: 10.3389/fonc.2015.00150. cited by applicant Wayne D. Newhauser et al., "The physics of proton therapy," Physics in Medicine & Biology, Mar. 24, 2015, 60 R155-R209, Institute of Physics and Enginee IOP Publishing, doi: 10.1088/0031-9155/60/8/R155. cited by applicant

S E McGowan et al., "Treatment planning optimisation in proton therapy," Br J Radiol, 2013, 86, 20120288, The British Institute of Radiology, 12 pages, DO 10.1259.bjr.20120288, cited by applicant

Steven Van De Water et al., "Towards FLASH proton therapy: the impact of treatment planning and machine characteristics on achievable dose rates," Acta O 2019, vol. 58, No. 10, p. 1462-1469, Taylor & Francis Group, DOI: 10.1080/0284186X.2019.1627416. cited by applicant

J. Groen, "FLASH optimisation in clinical IMPT treatment planning," MSc Thesis, Jul. 1, 2020, Erasmus University Medical Center, department of radiothera University of Technology, 72 pages. cited by applicant

Muhammad Ramish Ashraf et al., "Dosimetry for FLASH Radiotherapy: A Review of Tools and the Role of Radioluminescence and Cherenkov Emission," F Oncology, Aug. 21, 2020, vol. 8, Article 328, 20 pages, doi: 10.3389/fphy.2020.00328. cited by applicant

Emil Schuler et al., "Experimental Platform for Ultra-high Dose Rate FLASH Irradiation of Small Animals Using a Clinical Linear Accelerator," International Radiation Oncology, Biology, Physics, vol. 97, No. 1, Sep. 2016, pp. 195-203. cited by applicant

Elette Engels et al., "Toward personalized synchrotron microbeam radiation therapy," Scientific Reports, 10:8833, Jun. 1, 2020, 13 pages, DOI: https://doi.org/020-65729-z. cited by applicant

P-H Mackeprang et al., "Assessing dose rate distributions in VMAT plans" (Accepted Version), Accepted Version:

https://boris.unibe.ch/92814/8/dose\_rate\_project\_revised\_submit.pdf Published Version: 2016, Physics in medicine and biology, 61(8), pp. 3208-3221. Institut Publishing IOP, published Mar. 29, 2016, https://boris.unibe.ch/92814/. cited by applicant

Xiaoying Liang et al., "Using Robust Optimization for Skin Flashing in Intensity Modulated Radiation Therapy for Breast Cancer Treatment: A Feasibility Stu Radiation Oncology, vol. 10, Issue 1, p. 59-69, Published by Elsevier Inc., Oct. 15, 2019. cited by applicant

Alexei Trofimov et al., "Optimization of Beam Parameters and Treatment Planning for Intensity Modulated Proton Therapy," Technology in Cancer Research 2, No. 5, Oct. 2003, p. 437-444, Adenine Press. cited by applicant

Vladimir Anferov, "Scan pattern optimization for uniform proton beam scanning," Medical Physics, vol. 36, Issue 8, Aug. 2009, pp. 3560-3567, First published cited by applicant

Ryosuke Kohno et al., "Development of Continuous Line Scanning System Prototype for Proton Beam Therapy," International Journal of Particle Therapy, Ju Issue 4, p. 429-438, DOI: 10.14338/IJPT-16-00017.1. cited by applicant

Wenbo Gu et al., "Integrated Beam Orientation and Scanning-Spot Optimization in Intensity Modulated Proton Therapy for Brain and Unilateral Head and Ne Phys. Author manuscript; available in PMC Apr. 1, 2019 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904040/ Published in final edited form as: Med Phy 45(4): 1338-1350. Published online Mar. 1, 2018. doi: 10.1002/mp.12788 Accepted manuscript online: Feb. 2, 2018. cited by applicant

Paul Morel et al., "Spot weight adaptation for moving target in spot scanning proton therapy," Frontiers in Oncology, May 28, 2015, vol. 5, Article 119, 7 page 10.3389/fonc.2015.00119. cited by applicant

Simeon Nill et al., "Inverse planning of intensity modulated proton therapy," Zeitschrift fur Medizinische Physik, vol. 14, Issue 1, 2004, pp. 35-40, https://doi 3889-00198. cited by applicant

A. Lomax, "Intensity modulation methods for proton radiotherapy," Physics in Medicine & Biology, Jan. 1999, vol. 44, No. 1, pp. 185-205, doi: 10.1088/0032 cited by applicant

M Kramer et al., "Treatment planning for heavy-ion radiotherapy: physical beam model and dose optimization," Physics in Medicine & Biology, 2000, vol. 45 3317, doi: 10.1088/0031-9155/45/11/313. cited by applicant

Harald Paganetti, "Proton Beam Therapy," Jan. 2017, Physics World Discovery, IOP Publishing Ltd, Bristol, UK, 34 pages, DOI: 10.1088/978-0-7503-1370-4 Shinichi Shimizu et al., "A Proton Beam Therapy System Dedicated to Spot-Scanning Increases Accuracy with Moving Tumors by Real-Time Imaging and G Equipment Size," PLoS One, Apr. 18, 2014, vol. 9, Issue 4, e94971, https://doi.org/10.1371/journal.pone.0094971. cited by applicant

Heng Li et al., "Reducing Dose Uncertainty for Spot-Scanning Proton Beam Therapy of Moving Tumors by Optimizing the Spot Delivery Sequence," Interna Radiation Oncology, Biology, Physics, vol. 93, Issue 3, Nov. 1, 2015, pp. 547-556, available online Jun. 18, 2015, https://doi.org/10.1016/j.ijrobp.2015.06.015 Ion Beam Applications SA, "Netherlands Proton Therapy Center Delivers First Clinical Flash Irradiation," Imaging Technology News, May 2, 2019, Wainsco https://www.itnonline.com/content/netherlands-proton-therapy-center-delivers-first-clinical-flash-irradiation. cited by applicant

R. M. De Kruijff, "FLASH radiotherapy: ultra-high dose rates to spare healthy tissue," International Journal of Radiation Biology, 2020, vol. 96, No. 4, pp. 41 online: Dec. 19, 2019, https://doi.org/10.1080/09553002.2020.1704912. cited by applicant

Mevion Medical Systems, "Focus On The Future: Flash Therapy," Press Releases, Sep. 16, 2019, https://www.mevion.com/newsroom/press-releases/focus-fucited by applicant

Joseph D. Wilson et al., "Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold?", Frontiers in Oncology, Jan. 17, 2020, vol. 9, Article 19, 10.3389/fonc.2019.01563. cited by applicant David P. Gierga, "Is Flash Radiotherapy coming?", International Organization for Medical Physics, 2020, https://www.iomp.org/iomp-news2-flash-radiotherapy.

applicant
Abdullah Muhammad Zakaria et al., "Ultra-High Dose-Rate, Pulsed (FLASH) Radiotherapy with Carbon Ions: Generation of Early, Transient, Highly Oxygen

the Tumor Environment," Radiation Research, Dec. 1, 2020, vol. 194, Issue 6, pp. 587-593, Radiation Research Society, Published: Aug. 27, 2020, doi: https://doi.org/10.1667/RADE-19-00015.1. cited by applicant

Yusuke Demizu et al., "Carbon Ion Therapy for Early-Stage Non-Small-Cell Lung Cancer," BioMed Research International, vol. 2014, Article ID 727962, 9 p. Publishing Corporation, published: Sep. 11, 2014, https://doi.org/10.1155/2014/727962. cited by applicant

Ivana Dokic et al., "Next generation multi-scale biophysical characterization of high precision cancer particle radiotherapy using clinical proton, helium-, carb beams," Oncotarget, Aug. 30, 2016, vol. 7, No. 35, pp. 56676-56689, published online: Aug. 1, 2016, doi: 10.18632/oncotarget.10996. cited by applicant

Aetna Inc., "Proton Beam, Neutron Beam, and Carbon Ion Radiotherapy," 2020, No. 0270, http://www.aetna.com/cpb/medical/data/200\_299/0270.html. cited Nicholas W. Colangelo et al., "The Importance and Clinical Implications of FLASH Ultra-High Dose-Rate Studies for Proton and Heavy Ion Radiotherapy," I manuscript; available in PMC Jan. 1, 2021. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949397/ Published in final edited form as: Radiat Res. Jan. 2020 Published online Oct. 28, 2019. doi: 10.1667/RR15537.1. cited by applicant

Vincent Favaudon et al., "Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice," Science Trans Jul. 16, 2014, vol. 6, Issue 245, 245ra93, American Association for the Advancement of Science, DOI: 10.1126/scitranslmed.3008973. cited by applicant "FlashRad: Ultra-high dose-rate FLASH radiotherapy to minimize the complications of radiotherapy," 2014, https://siric.curie.fr/sites/default/files/atoms/files by applicant

Tami Freeman, "FLASH radiotherapy: from preclinical promise to the first human treatment," Physics World, Aug. 6, 2019, IOP Publishing Ltd, https://physicsworld.com/a/flash-radiotherapy-from-preclinical-promise-to-the-first-human-treatment/. cited by applicant

Intraop Medical, Inc., "IntraOp and Lausanne University Hospital Announce Collaboration in FLASH radiotherapy," Jun. 18, 2020, https://intraop.com/news-university-flash-radiotherapy-collaboration/. cited by applicant

M.-C. Vozenin et al., "Biological Benefits of Ultra-high Dose Rate FLASH Radiotherapy: Sleeping Beauty Awoken," Clin Oncol (R Coll Radiol). Author mar PMC Nov. 12, 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850216/ Published in final edited form as: Clin Oncol (R Coll Radiol). Jul. 2019; 31(7) Published online Apr. 19, 2019. doi: 10.1016/j.clon.2019.04.001. cited by applicant

Efstathios Kamperis et al., "A FLASH back to radiotherapy's past and then fast forward to the future," J Cancer Prev Curr Res. 2019; 10(6): 142-144. published DOI: 10.15406/jcpcr.2019.10.00407. cited by applicant

P. Symonds et al., "FLASH Radiotherapy: The Next Technological Advance in Radiation Therapy?", Clinical Oncology, vol. 31, Issue 7, p. 405-406, Jul. 1, 20 College of Radiologists, Published by Elsevier Ltd., DOI: https://doi.org/10.1016/j.clon.2019.05.011. cited by applicant

Swati Girdhani et al., "Abstract LB-280: FLASH: A novel paradigm changing tumor irradiation platform that enhances therapeutic ratio by reducing normal ti activating immune pathways," Proceedings: AACR Annual Meeting 2019; Mar. 29-Apr. 3, 2019; Atlanta, GA, published Jul. 2019, vol. 79, Issue 13 Supplementary Association for Cancer Research, DOI: https://doi.org/10.1158/1538-7445.AM2019-LB-280. cited by applicant

Bazalova-Carter et al., "On the capabilities of conventional x-ray tubes to deliver ultra-high (FLASH) dose rates," Med. Phys. Dec. 2019; 46 (12):5690-5695, 2019, American Association of Physicists in Medicine, doi: 10.1002/mp.13858. Epub Oct. 23, 2019. PMID: 31600830. cited by applicant

Manuela Buonanno et al., "Biological effects in normal cells exposed to FLASH dose rate protons," Radiother Oncol. Author manuscript; available in PMC C https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728238/ Published in final edited form as: Radiother Oncol. Oct. 2019; 139: 51-55. Published online Mar. 5 10.1016/j.radonc.2019.02.009. cited by applicant

N. Rama et al., "Improved Tumor Control Through T-cell Infiltration Modulated by Ultra-High Dose Rate Proton FLASH Using a Clinical Pencil Beam Scan System," International Journal of Radiation Oncology, Biology, Physics, vol. 105, Issue 1, Supplement, S164-S165, Sep. 1, 2019, Mini Oral Sessions, DOI: https://doi.org/10.1016/j.ijrobp.2019.06.187. cited by applicant

Inserm Press Office, "Radiotherapy 'flashes' to reduce side effects," Press Release, Jul. 16, 2014, https://presse.inserm.fr/en/radiotherapy-flashes-to-reduce-sic cited by applicant

Eric S. Diffenderfer et al., "Design, Implementation, and in Vivo Validation of a Novel Proton FLASH Radiation Therapy System," International Journal of R Biology, Physics, vol. 106, Issue 2, Feb. 1, 2020, pp. 440-448, Available online Jan. 9, 2020, Published by Elsevier Inc., DOI: https://doi.org/10.1016/j.ijrobp. by applicant

by applicant Valerie Devillaine, "Radiotherapy and Radiation Biology," Institut Curie, Apr. 21, 2017, https://institut-curie.org/page/radiotherapy-and-radiation-biology. cite Imaging Technology News, "ProNova and medPhoton to Offer Next Generation Beam Delivery, Advanced Imaging for Proton Therapy," Oct. 6, 2014, Wainst https://www.itnonline.com/content/pronova-and-medphoton-offer-next-generation-beam-delivery-advanced-imaging-proton-therapy. cited by applicant

nttps://www.utnonline.com/content/pronova-and-medphoton-offer-next-generation-beam-delivery-advanced-imaging-proton-therapy. Cited by applicant Oncolink Team, "Radiation Therapy: Which type is right for me?", OncoLink Penn Medicine, last reviewed Mar. 3, 2020, Trustees of the University of Penns https://www.oncolink.org/cancer-treatment/radiation/introduction-to-radiation-therapy/radiation-therapy-which-type-is-right-for-me. cited by applicant

Marco Durante et al., "Faster and safer? FLASH ultra-high dose rate in radiotherapy," Br J Radiol 2018; 91(1082):20170628, British Institute of Radiology, P Dec. 15, 2017, https://doi.org/10.1259/bjr.20170628. cited by applicant

John R. Fischer, "PMB launches FLASH radiotherapy system for use in clinical trials," HealthCare Business News, Jun. 29, 2020, DOTmed.com, Inc., https://www.dotmed.com/news/story/51662. cited by applicant

Marie-Catherine Vozenin et al., "The advantage of FLASH radiotherapy confirmed in mini-pig and cat-cancer patients," Clinical Cancer Research, Author Ma OnlineFirst Jun. 6, 2018, https://clincancerres.aacrjournals.org/content/clincanres/early/2018/06/06/1078-0432.CCR-17-3375.full.pdf. cited by applicant

Primary Examiner: Matthews; Christine H

Attorney, Agent or Firm: Harness, Dickey & Pierce, P.L.C.

## **Background/Summary**

#### **FIELD**

- (1) Embodiments of the present invention generally relate to the field of radiotherapy treatment and systems for same. More specifically, embodiments of the present invention relate to systems and methods for proton therapy treatment planning. BACKGROUND
- (2) Particle therapy with protons or other ions is a type of radiotherapy that uses an external beam to provide targeted ionizing radiation to a tumor. Protons or other positively charged ions are sent to an accelerator to bring the particles' energy to a predetermined value. The protons or other ions then move through a beam-transport system, where magnets are used to shape, focus and/or direct the proton beam or other ion beam as necessary.
- (3) Standard radiation therapy systems deposit energy in "spots" along the path of the beam to a target tumor. However, the reach of the energy also extends beyond the target tumor, and may deliver radiation to healthy tissue around the tumor site. This excess radiation may damage normal tissue or organs near the target area. Moreover, the selection of specific energies and the number of spots are decided based only on patient geometry and hardware constraints. The subsequent optimization to achieve the dosimetric criteria for treatment is traditionally performed only on spot intensities, which can produce less than optimal results. It is appreciated that the term spot intensity is used here as a synonym to monitor unit count, e.g., the intensity is a relative quantity proportional to the number of protons per spot, as delivered by the treatment machine.
- (4) Radiation treatment plans can be optimized according to given dose volume objectives for target volume and organs at risk and according to plan robustness using commercially available treatment planning systems. Dose distributions are calculated using beam characteristics and a machine specific dose calibration. However, machine or system limitations can lead to a translation of an aimed dose distribution into machine/treatment delivery system parameters that may generate an unacceptable treatment plan. Additionally, the generated treatment plan may not use the full system/machine capability to make use of the system in the most efficient and reliable manner. The treatment plan can be optimized for efficiency and may employ a trial-and-error modification of several complex associated plan parameters (e.g., energy layer distance, spot size or spot spacing) required for multi-directional optimization. Even if an optimized treatment plan finally passes the criteria for plan quality and treatment delivery time, the manual trial and-error-process is time consuming and may not be able to achieve the optimal delivery efficiency.
- (5) More specifically, particle therapy planning using existing techniques is constrained by the delivery of doses in discrete, predetermined increments. For example, to deliver dose to a 3D volume, multiple discrete beam energies are required and further, the dose with energy must be delivered in discrete spots. Traditionally, the discretization scheme, including the selection of specific energies, the number of spots, and their locations, are decided based on patient geometry and hardware constraints, and the treatment planning optimization is limited by these constraints. Rather, the subsequent optimization to achieve the dosimetric criteria for treatment is traditionally performed only on spot intensities. Because there is a lower limit for the intensity per each spot, the layers used to deliver the dose will only include a relatively low number of spots. This often disadvantageously results in an uneven dose distribution, which is considered clinically suboptimal.
- (6) Because layer energies are pre-determined by existing treatment planning solutions, there is nothing the optimization algorithm can do to resolve these constraints. Therefore, what is needed is an approach to particle therapy treatment that discretizes layers and spots using an optimization algorithm without the existing constraints, that produces an optimal distribution of layer energies and spots with a smoother (e.g., more even) dose distribution, and that can advantageously produce fewer layers and potentially fewer spots, thereby reducing the time taken to treat a patient. Therefore, what is needed is an approach to particle therapy treatment that addresses these issues. SUMMARY
- (7) More specifically, what is needed is an approach to particle therapy treatment that discretizes layers and spots using an optimization algorithm without the existing constraints, that produces an optimal distribution of layer energies and spots with a smoother (e.g., more even) dose distribution, and that can advantageously produce fewer layers and potentially fewer spots, thereby reducing the time required to treat a patient. Accordingly, methods and systems for proton therapy planning that include proton energy and spot optimization that discretizes layers and spots using an optimization algorithm to produce an optimal distribution of layer energies and spots with a relatively smooth dose distribution are disclosed herein. Embodiments of the present invention can thereby produce fewer layers and potentially fewer spots, thereby advantageously reducing the time required to treat a patient.
- (8) According to one embodiment, a system for proton therapy treatment is disclosed. The system includes a gantry including a nozzle emitting a controllable proton beam, a proton therapy treatment system that controls the gantry according to a treatment plan, and a treatment planning system including a memory, and a processor operable to perform a method for generating the treatment plan. The method includes receiving treatment planning parameters, determining a number of spots and energy levels of the spots according to the treatment planning parameters, calculating intensities for the spots according to the energy levels, discretizing the spots into a plurality of blocks according to a location of the spots and the intensities of the spots, wherein the treatment plan comprises the blocks, and where the block represent an energy layer applied by the gantry, and outputting the treatment plan.
- (9) According to some embodiments, the method includes treating a patient using the gantry according to the treatment plan.
- (10) According to some embodiments, the discretizing the spots into a plurality of blocks is performed iteratively until a clinical goal is achieved.
- (11) According to some embodiments, the method includes determining a plurality of angles for performing proton therapy treatment and where the determining a number of spots and energy levels of the spots is further based on the plurality of angles.
- (12) According to some embodiments, the method includes receiving the number of layers as user input, where the determining a number of spots and energy levels of the spots is further based on the number of layers.
- (13) According to some embodiments, the method includes sorting the spots according to depth before discretizing the spots.
- (14) According to some embodiments, the method includes sorting the spots according to energy level before discretizing the spots.
- (15) According to some embodiments, the energy layers have a fixed width.
- (16) According to some embodiments, the method includes the energy layers have a fixed intensity.
- (17) According to another embodiment, a method for proton therapy treatment is disclosed. The method includes receiving treatment planning parameters, determining a number of spots and energy levels of the spots according to the treatment planning parameters, sorting the spots based on a depth of a respective spot, calculating intensities for the spots according to the energy levels, discretizing the spots into a plurality of blocks according to a location of the spots and the intensities of the spots, where each block represents an energy layer applied by the gantry, and outputting the treatment plan, wherein the treatment plan comprises the blocks.
- (18) According to a different embodiment, a non-transitory computer-readable storage medium having embedded therein program instructions, which

when executed by one or more processors of a device, causes the device to execute a method for proton therapy treatment. The method includes receiving treatment planning parameters, determining a number of spots and energy levels of the spots according to the treatment planning parameters, sorting the spots based on a depth of a respective spot, calculating intensities for the spots according to the energy levels, discretizing the spots into a plurality of blocks according to a location of the spots and the intensities of the spots, where each block represents an energy layer applied by the gantry, and outputting the treatment plan, wherein the treatment plan comprises the blocks.

# Description

#### BRIEF DESCRIPTION OF THE DRAWINGS

- (1) The accompanying drawings, which are incorporated in and form a part of this specification, illustrate embodiments of the invention and, together with the description, serve to explain the principles of the invention:
- (2) FIG. 1 shows a block diagram of an example of a computing system upon which the embodiments described herein may be implemented.
- (3) FIG. 2 is a block diagram showing selected components of a radiation treatment system upon which embodiments according to the present invention can be implemented.
- (4) FIG. 3 illustrates elements of a radiation treatment system in accordance with embodiments according to the invention.
- (5) FIG. **4** is a block diagram illustrating components in a process for creating an optimized proton therapy treatment plan in embodiments according to the present invention.
- (6) FIG. 5 is a flow-chart depicting an exemplary sequence steps for automatically creating an optimized proton therapy treatment plan according to embodiments of the present invention.
- (7) FIG. **6** is a diagram of an exemplary proton therapy treatment plan with predetermined energy layers.
- (8) FIG. **7** is a diagram of an exemplary proton therapy treatment plan optimized according to a spot distribution using customized energy layers having a fixed intensity per layer.

#### **DETAILED DESCRIPTION**

- (9) Reference will now be made in detail to several embodiments. While the subject matter will be described in conjunction with the alternative embodiments, it will be understood that they are not intended to limit the claimed subject matter to these embodiments. On the contrary, the claimed subject matter is intended to cover alternative, modifications, and equivalents, which may be included within the spirit and scope of the claimed subject matter as defined by the appended claims.
- (10) Furthermore, in the following detailed description, numerous specific details are set forth in order to provide a thorough understanding of the claimed subject matter. However, it will be recognized by one skilled in the art that embodiments may be practiced without these specific details or with equivalents thereof. In other instances, well-known methods, procedures, components, and circuits have not been described in detail as not to unnecessarily obscure aspects and features of the subject matter.
- (11) Portions of the detailed description that follows are presented and discussed in terms of a method. Although steps and sequencing thereof are disclosed in a figure herein describing the operations of this method, such steps and sequencing are exemplary. Embodiments are well suited to performing various other steps or variations of the steps recited in the flowchart (e.g., FIG. 5) of the figures herein, and in a sequence other than that depicted and described herein.
- (12) Some portions of the detailed description are presented in terms of procedures, steps, logic blocks, processing, and other symbolic representations of operations on data bits that can be performed on computer memory. These descriptions and representations are the means used by those skilled in the data processing arts to most effectively convey the substance of their work to others skilled in the art. A procedure, computer-executed step, logic block, process, etc., is here, and generally, conceived to be a self-consistent sequence of steps or instructions leading to a desired result. The steps are those requiring physical manipulations of physical quantities. Usually, though not necessarily, these quantities take the form of electrical or magnetic signals capable of being stored, transferred, combined, compared, and otherwise manipulated in a computer system. It has proven convenient at times, principally for reasons of common usage, to refer to these signals as bits, values, elements, symbols, characters, terms, numbers, or the like.
- (13) It should be borne in mind, however, that all of these and similar terms are to be associated with the appropriate physical quantities and are merely convenient labels applied to these quantities. Unless specifically stated otherwise as apparent from the following discussions, it is appreciated that throughout, discussions utilizing terms such as "generating," "writing," "including," "storing," "transmitting," "traversing," "associating," "identifying," "optimizing" or the like, refer to the action and processes of a computer system, or similar electronic computing device, that manipulates and transforms data represented as physical (electronic) quantities within the computer system's registers and memories into other data similarly represented as physical quantities within the computer system memories or registers or other such information storage, transmission or display devices.
- (14) Some embodiments may be described in the general context of computer-executable instructions, such as program modules, executed by one or more computers or other devices. Generally, program modules include routines, programs, objects, components, data structures, etc. that perform particular tasks or implement particular abstract data types. Typically the functionality of the program modules may be combined or distributed as desired in various embodiments.
- (15) Energy and Spot Optimization for Proton Therapy Treatment
- (16) The following description is presented to enable a person skilled in the art to make and use the embodiments of this invention; it is presented in the context of a particular application and its requirements. Various modifications to the disclosed embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be applied to other embodiments and applications without departing from the spirit and scope of the present disclosure. Thus, the present invention is not limited to the embodiments shown, but is to be accorded the widest scope consistent with the principles and features disclosed herein.
- (17) Methods and systems for proton therapy planning including proton energy and spot optimization that discretizes layers and spots using an optimization process are described herein. The optimization process produces an optimal distribution of layer energies and spots with a relatively smooth dose distribution, and can freely choose the number of spots and the energy levels of the spots. In this way, each spot can be treated as its own layer and is not constrained by the requirements of other spots/layers. Thereafter, the spots defined by the process can be sorted into a list according to energy levels/depths, and the spots can be grouped into blocks. The blocks can be assigned energy levels based on the corresponding spots, for example, using an average of all of the spots associated with the block. The blocks are then used to define the energy levels applied by the proton therapy treatment system.
- (18) Embodiments of the present invention can thereby produce fewer layers and potentially fewer spots, thereby advantageously reducing the time required to treat a patient. The optimization processes, e.g., algorithms, described herein can split individual spots among different layers to avoid creating spots that are below the minimum energy threshold deliverable by the treatment system. The spots can be divided into layers such that the layers receive substantially equal intensities. For example, the spots can be divided into layers so that each layer receives a substantially equal number of protons delivered by the proton therapy treatment system. In general, a treatment plan that is optimized using fewer layers leads to a faster delivery time. On the other hand, embodiments of the present invention can also optimize proton treatment plans for accuracy by using more spots and/or layers to better fit the target volume. The spots can be distributed at fixed intervals (e.g., 3 mm spacing) or distributed based on variations such as beam energy and/or beam range. In all cases, the general principle holds that the intensity of a layer is the sum of the intensities of all spots

on a given layer.

(19) FIG. 1 shows a block diagram of an example of a computing system 100 upon which the embodiments described herein may be implemented. In a basic configuration, the system 100 includes at least one processing unit 102 and a memory 104. This most basic configuration is illustrated in FIG. 1 by dashed line 106. The system 100 may also have additional features and/or functionality. For example, the system 100 may also include additional storage (removable and/or non-removable) including, but not limited to, magnetic or optical disks or tape. Such additional storage is illustrated in FIG. 1 by removable storage 108 and non-removable storage 120. The system 100 may also contain communications connection(s) 122 that allow the device to communicate with other devices, e.g., in a networked environment using logical connections to one or more remote computers.

- (20) The system **100** of FIG. **1** also includes input device(s) **124** such as keyboard, mouse, pen, voice input device, touch input device, etc. Output device(s) **126** such as a display device, speakers, printer, etc., are also included.
- (21) In the example of FIG. 1, the memory 104 includes computer-readable instructions, data structures, program modules, and the like. Depending on how it is to be used, the system 100—by executing the appropriate instructions or the like—can be used to implement a planning system used that discretizes layers and spots using an optimization algorithm (comprising computer readable instructions) to produce an optimal distribution of layer energies and spots with a relatively smooth dose distribution. The treatment planning algorithms executed by CPU 102 can freely choose the number of spots and the energy levels of the spots so that each spot can be treated as its own layer unconstrained by the requirements of other spots/layers. Thereafter, the spots defined by the algorithm can be sorted in a list according to energy levels/depth using CPU 102, and the spots can be grouped into blocks. The blocks can be assigned energy levels based on corresponding spots, for example, using an average of all spots associated with the block. More generally, system 100 can be used to generate and/or optimize proton therapy treatment plans in accordance with the present invention. (22) FIG. 2 is a block diagram showing selected components of a radiation treatment system 200 upon which embodiments according to the present invention can be implemented. In the example of FIG. 2, the system 200 includes an accelerator and beam transport system 204 that generate and/or accelerate a beam 201. Embodiments according to the invention can generate and deliver beams of various types including, for instance, proton beams, electron beams, neutron beams, photon beams, ion beams, or atomic nuclei beams (e.g., using elements such as carbon, helium, or lithium) and the like. The operations and parameters of the accelerator and beam transport system 204 are controlled so that the intensity, energy, size, and/or shape of the beam are dynamically modulated or controlled during treatment of a patient according to an optimized radiation treatment plan
- (23) A recent radiobiology study has demonstrated the effectiveness of delivering an entire, relatively high therapeutic radiation dose to a target within a single, short period of time. This type of treatment is referred to generally herein as FLASH radiation therapy (FLASH RT). Evidence to date suggests that FLASH RT advantageously spares normal, healthy tissue from damage when that tissue is exposed to only a single irradiation for only a very short period of time. For FLASH RT, the accelerator and beam transport system **204** can generate beams that can deliver at least four (4) grays (Gy) in less than one second, and may deliver as much as 20 Gy or 50 Gy, or more, in less than one second. The control system **210** can execute a treatment plan for FLASH RT, and the plan can be generated or optimized by system **100** executing an optimization algorithm in accordance with embodiments of the present invention.
- (24) The nozzle **206** is used to aim the beam toward various locations (a target) within a patient supported on the patient support device **208** (e.g., a chair, couch, or table) located in a treatment room. A target may be an organ, a portion of an organ (e.g., a volume or region within the organ), a tumor, diseased tissue, or a patient outline, for instance.
- (25) The nozzle **206** may be mounted on or may be a part of a gantry (FIG. **3**) that can be moved relative to the patient support device **208**, which may also be moveable. In embodiments, the accelerator and beam transport system **204** are also mounted on, or are a part of, the gantry structure; in another embodiment, the accelerator and beam transport system are separate from (but in communication with) the gantry structure.
- (26) The control system 210 of FIG. 2 receives and implements a prescribed treatment plan generated and/or optimized according to embodiments of the present invention. In embodiments, the control system 210 includes a computing system having a processor, memory, an input device (e.g., a keyboard), and perhaps optionally a display; the system 100 of FIG. 1 is an example of such a platform for the control system 210. The control system 210 can receive data regarding the operation of the system 200. The control system 210 can control parameters of the accelerator and beam transport system 204, nozzle 206, and patient support device 208, including parameters such as the energy, intensity, size, and/or shape of the beam, direction of the nozzle, and position of the patient support device (and the patient) relative to the nozzle, according to data the control system 210 receives and according to the radiation treatment plan.
- (27) FIG. 3 illustrates elements of a radiation treatment system 300 for treating a patient 304 in embodiments according to the present invention. The system 300 is an example of an implementation of the radiation treatment system 200 of FIG. 2, for example. In embodiments, the gantry 302 and nozzle 306 can be moved up and down the length of the patient 304 and/or around the patient, and the gantry and nozzle can move independently of one another. While the patient 304 is supine in the example of FIG. 3, the invention is not so limited to this orientation. For example, the patient 304 can instead be seated in a chair or standing. The gantry 302 can be controlled by a treatment system using an optimized treatment plan generated according to embodiments of the present invention.
- (28) With regard to FIG. **4**, an exemplary proton therapy system **400** for imaging and treating a patient **304** is depicted according to embodiments of the present invention. In the example of FIG. **4**, patient **304** is imaged using an image system **402** that uses, for example, x-rays, magnetic resonance imaging (MRI), and computed tomography (CT). When CT or MRI imagery, for example, is used, a series of two-dimensional (2D) images are taken from a 3D volume. Each 2D image is an image of a cross-sectional "slice" of the 3D volume. The resulting collection of 2D cross-sectional slices can be combined to create a 3D model or reconstruction of the patient's anatomy (e.g., internal organs). The 3D model will contain organs of interest, which may be referred to as structures of interest herein. Those organs of interest include the organ targeted for radiation therapy (a target), as well as other organs that may be at risk of radiation exposure during treatment. According to some embodiments, the imaging process is a separate process from the treatment planning process, and the treatment planning process can include receiving imaging data from a prior imaging session, for example.
- (29) One purpose of the 3D model is the preparation of a radiation treatment plan. To develop a patient-specific radiation treatment plan, information is extracted from the 3D model to determine parameters such as organ shape, organ volume, tumor shape, tumor location in the organ, and the position or orientation of several other structures of interest as they relate to the affected organ and any tumor. The radiation treatment plan can specify, for example, how many radiation beams to use and from which angle each of the beams will be delivered.
- (30) In embodiments according to the present invention, the images from the image system **402** are input to a planning system **404**. In embodiments, the planning system **404** includes a computing system having a processor, memory, an input device (e.g., a keyboard), and a display. The system **100** of FIG. **1** is an example of a platform for the planning system **404**.
- (31) Continuing with reference to FIG. **4**, the planning system **404** executes software that is capable of producing an optimized treatment plan for treating patient **304**. The treatment planning system **404** can receive imagery data generated by image system **402** to determine constraints regarding patient anatomy along with treatment planning parameters, such as other patient-related data and machine parameters. The treatment planning parameters are discretized into spots with defined energy levels, and the spots are sorted according to their depth/energy level. The planning system **404** can optimize the treatment plan according to an optimization algorithm that determines an optimal distribution of layers with a relatively smooth dose distribution. The treatment plan can be optimized in accordance with various prescribed results. For instance, the treatment plan can be optimized to use fewer layers leading to a faster delivery time, or can be optimized for accuracy or 3D dose homogeneity by using more layers to conform to the target volume. The planning system **404** can also receive user input that defines the number of layers used in the optimized plan **408**,

for example.

(32) The treatment planning system **404** outputs an optimized plan **408** according to an iterative optimizing algorithm **406** as described herein according to embodiments of the present invention. The spots can be distributed at fixed intervals (e.g., 3 mm spacing) or based on variations such as beam energy and/or beam range, and the spots are added to a list of spots that is sorted according to energy level or depth of the spot. Based on the energy levels of the spots and/or the depth/location of a spot, the spots are assigned intensities, where the intensity of a layer is the sum of the intensities of all spots of the layer. The spots are then discretized into blocks according to the energies and intensities, where each block represents a distinct layer. Discretizing the spots into blocks can be an iterative process that is performed repeatedly until a clinical goal or optimization goal is achieved. The optimized plan **408** is then used to configure treatment system **300** for performing proton therapy treatment on patient **304** using gantry **302**, for example.

- (33) With regard to FIG. 5, an exemplary sequence of computer implemented steps for automatically generating a proton therapy treatment plan is depicted according to embodiments of the present invention. The treatment plan receives treatment planning parameters at step 501, and the parameters may include patient anatomy data and machine parameters. The treatment planning parameters are discretized into spots with defined energy levels at step 502. At this point each spot may have a separate energy level. At step 503, the spots are added to a list of spots and the list is sorted according to energy level or depth of the spot. An optimization algorithm is executed at step 504 to produce an optimal distribution of layer energies and spots with a relatively smooth dose distribution. The spots can be distributed at fixed intervals (e.g., 3 mm spacing) or based on variations such as beam energy and/or beam range, and specifically, the distribution can be based on the energy levels of the spots and/or the depth/location of a spot, the spots are assigned intensities, where the intensity of a layer is the sum of the intensities of all spots of the layer. The spots are then discretized into blocks according to the energies, intensities, and the location of the spots, and each block (705 in FIG. 7) represents a distinct energy layer to be applied by a proton therapy system. Discretizing the spots into blocks can be an iterative process that is performed repeatedly until a clinical goal or optimization goal is achieved.
- (34) At step **505**, the optimized treatment plan is output, for example, as a computer readable data file. The data file can be stored in memory and used by a proton therapy treatment system to emit a controllable proton beam according to the treatment plan, using a gantry, for example. (35) According to some embodiments, the optimization algorithm also determines optimal beam angles for a clinical goal or optimization goal and the spots are generated and discretized according to the beam angles.
- (36) With regard to FIG. **6**, an exemplary proton therapy treatment plan **600** applied to a target volume **602** (e.g., a tumor or organ) surrounded by normal tissue **601** for proton therapy treatment is depicted. The treatment plan is generated using limited optimization based on dose volume objectives for the target volume **602** and organs at risk (e.g., normal tissue **601**), and machine parameters. Dose distributions are calculated according to the constraints of beam characteristics of proton beam **604** and a machine specific dose calibration. However, the treatment plan depicted in FIG. **6** may not use the full system/machine capability to make use of the system in the most efficient and reliable manner. Moreover, the application of treatment plan **600** at the machine may fail or not achieve the optimal delivery efficiency as requested by plan objectives during treatment planning due to machine specific capability limitations of combined plan parameters that are not taken into account.
- (37) As depicted in FIG. **6**, the treatment plan is constrained because it is limited to fixed energy layers for discretizing spots produced by proton beam **604** for treating the target volume **602**. The energy levels of the predefined layers are defined based on limited considerations of the patient anatomy and characteristics of the treatment device, and a scanning pattern using layers **603** is applied by beam **604** based on these characteristics. Furthermore, using this approach, the deepest layer of the target **602** receives the highest intensity, and layers closer to the surface receive significantly lower intensity, making it difficult to optimize for the surface layers.
- (38) Moreover, using the approach depicted in FIG. **6**, no less than a certain minimum intensity can be applied to a single spot. Therefore, after optimization, if the intensity of a spot is less than the minimum intensity, the spot must be removed from the plan to generate a plan that is deliverable by the machine. If all spots of an energy layer are below the minimum intensity, the entire layer may need to be removed. A simple removal of spots/layers can change the treatment plan such that the dose distribution is no longer optimal. Moreover, failure to remove these spots or layers from the treatment plan during the planning phase may lead to a failure of the treatment, in which case the treatment must be stopped and restarted after the layer is removed. A more efficient approach involves customizing the number of layers and positioning them as necessary to achieve the clinical objectives, as depicted in FIGS. **7** and **8** below.
- (39) With regard to FIG. 7, an exemplary optimized proton therapy treatment plan 700 applied to a target volume 702 (e.g., a tumor or organ) surrounded by normal tissue 701 for proton therapy treatment is depicted. The treatment plan 700 is initially discretized to layers as if there is infinite number of layers, and an iterative optimization process distributes spots using the layers to achieve the clinical goal of treatment plan 700 and ensures that the plan is actually deliverable by the treatment device (e.g., gantry 302). According to some embodiments, an input number of layers is received as user input (for instance). The optimization algorithm then places the spots in a list sorted by range/energy level, and calculates intensities for each spot (e.g., based on energy level/depth) to determine an resultant (e.g., optimal) distribution of layers for achieving the clinical goal of treatment plan 700 using proton beam 704. As depicted in FIG. 7, the treatment plan 700 includes 6 layers 703, and each layer applies ½ of the total intensity (number of protons) of treatment plan 700. In this way, the intensities of the layers are fixed, and the spacing of the layers in unconstrained. Splitting the spots among the layers using the principle of equal layer intensities avoids creating spots and layers that are below the minimum intensity deliverable by the treatment system. Note that the principle of equal layer intensities is used here as an example only and other principles could be used to distribute the spots into energy layers. For example, an arbitrary energy-dependent function could be designed to distribute the intensity of the energy layers unevenly. In general, a treatment plan that is optimized using fewer layers leads to a faster delivery time. Moreover, optimizing the treatment plan for accuracy tends to use more layers to better fit the target volume. The spots can be distributed at fixed intervals (e.g., 3 mm spacing) using proton beam 704, or can be distributed based on variations such as beam energ
- (40) According to some embodiments, the distribution of the layers and/or the energy levels thereof are manually defined by a user. The user-defined energy levels can include layers with an intensity equal to 0 such that no protons are delivered at certain energies, and these layers can be automatically removed by the treatment planning system after the optimization process. The layers can be defined by the user at fixed distances, or custom distances, for example.
- (41) Embodiments of the present invention are thus described. While the present invention has been described in particular embodiments, it should be appreciated that the present invention should not be construed as limited by such embodiments, but rather construed according to the following claims.

## Claims

1. A system for proton therapy treatment, the system comprising: a gantry including a nozzle configured to emit a controllable proton beam; a proton therapy treatment system configured to automatically control the gantry according to a treatment plan; and a treatment planning system including a memory, and a processor configured to receive treatment planning parameters, determine a quantity of spots, among a plurality of spots, according to the treatment planning parameters, determine an energy for each spot, among the plurality of spots, according to the treatment planning parameters, calculate intensities for the plurality of spots according to the energy for each spot, among the plurality of spots, discretize the plurality of spots into a plurality of blocks according to locations of the plurality of spots and intensities of the plurality of spots to generate the treatment plan, wherein the treatment plan includes the plurality of blocks, among the plurality of blocks, represents an energy layer, among a number of energy

layers, applied by the controllable proton beam, and output the treatment plan to the proton therapy treatment system to perform the proton therapy treatment; wherein the proton therapy treatment system is configured to automatically control at least one of an intensity, energy, size or shape of the controllable proton beam emitted by the nozzle according to the treatment plan.

- 2. The system as described in claim 1, wherein the system is configured to treat a patient using the gantry according to the treatment plan.
- 3. The system as described in claim 1, wherein the processor is configured to iteratively repeat the discretizing of the plurality of spots until a clinical goal is achieved.
- 4. The system as described in claim 1, wherein the processor is configured to determine a plurality of angles for performing the proton therapy treatment, and determine the quantity of spots and the energy for each spot according to the treatment planning parameters and the plurality of angles.
- 5. The system as described in claim 1, wherein the processor is configured to receive the number of energy layers as user input, and determine the quantity of spots and the energy for each spot according to the treatment planning parameters and the number of energy layers.
- 6. The system as described in claim 1, wherein the processor is configured to sort the plurality of spots according to depth before discretizing the plurality of spots.
- 7. The system as described in claim 1, wherein the processor is configured to sort the plurality of spots according to the energy of each spot before discretizing the plurality of spots.
- 8. The system as described in claim 1, wherein the energy layers are spaced apart from one another by a fixed spacing.
- 9. The system as described in claim 1, wherein the energy layers have a fixed total intensity.
- 10. The system of claim 1, wherein each energy layer, among the number of energy layers, has the same intensity as other energy layers among the number of energy layers.